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Abstract 
Review on THRB, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: C-ERBA-2, C-ERBA-BETA, 
ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, 
THRB2 
HGNC (Hugo): THRB 
Location: 3p24.2 
Local order: According to the NCBI map viewer 
genes flanking THRB (3p24.2) from telomere to 
centromere are: UBE2E2-AS1 (UBE2E2-AS1 
UBE2E2 antisense RNA 1 (head to head)), 
UBE2E2 (ubiquitin-protein ligase E2), 
LOC100420471 (ADP-ribosylation factor-like 4A 
pseudogene), UBE2E1 (ubiquitin carrier protein 
E1), NKIRAS1 (NFKB inhibitor interacting Ras-
like 1), RPL15 (ribosomal protein L15), NR1D2 
(nuclear receptor subfamily 1, group D, member 2), 
NPM1P23 (LOC100422256, nucleophosmin 1 
(nucleolar phosphoprotein B23, numatrin) 
pseudogene 23), LINC00691 (LOC152024, long 
intergenic non-protein coding RNA 691), and intra-
THRB: LOC101927854 (uncharacterized 
LOC101927854) sharing some exons with two 
transcript variants (GeneBank: CB994391.1, 
AW950510.1) present in ACE View description of 
NR1D2 gene locus, RPL31P20 (ribosomal protein 
L31 pseudogene 20), THRB-IT1 (THRB intronic 
transcript 1), THRB-AS1 (LOC644990, THRB 
antisense RNA 1), at 5' side of THRB: MIR4792 
(microRNA 4792), EIF3KP2 (eukaryotic 
translation initiation factor 3, subunit K pseudogene 
2), LOC101927874 (uncharacterized  
LOC101927874), RNA5SP125 (RNA, 5S 
ribosomal pseudogene 125), RARB (retinoic acid 
receptor, beta), CFL1P7 (cofilin 1 (non-muscle) 
pseudogene 7), RNA5SP126 (RNA, 5S ribosomal 
pseudogene 126), LOC100505947 (uncharacterized 
LOC100505947), TOP2B (topoisomerase (DNA) II 
beta 180kDa), MIR4442 (microRNA 4442), 
CRIP1P2 (cysteine-rich protein 1 (intestinal) 
pseudogene 2), NGLY1 (N-glycanase 1), 
RPL32P11 (ribosomal protein L32 pseudogene 11), 
TAF9BP1 (TAF9B RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 31kDa 
pseudogene 1), OXSM (3-oxoacyl-ACP synthase, 
mitochondrial), LINC00692 (long intergenic non-
protein coding RNA 692), RPEP2 (ribulose-5-
phosphate-3-epimerase pseudogene 2), HMGB3P12 
(high mobility group box 3 pseudogene 12), 
VENTXP4 (VENT homeobox pseudogene 4), see 
diagram 1. 
Note 
The human thyroid hormone receptor beta (THRB), 
a member of several nuclear receptors for thyroid 
hormone, has been shown to mediate the biological 
activities of triiodothyronine (T3). This gene 
encodes 3 protein isoforms, the TRβ1, TRβ2, and 
TRβ4 differentially expressed in developmental and 
tissue-specific patterns and implicated in regulation 
of transcription of target genes affecting multiple 
physiological processes, including cell growth, 
differentiation, apoptosis, and maintenance of 
metabolic homeostasis. The gene controls thyroid 
hormone levels, liver and kidney metabolism and is 
critical for normal development of auditory and 
visual systems. The THRB has been also implicated 
in the pathology of numerous diseases including 
thyroid hormone resistance syndrome (RTH), 
obesity, neurodegenerative disorders and cancer.  
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Diagram 1. Schematic representation of human chromosome 3 indicating the position of THRB locus (red bar). The 
official symbols, NCBI IDs and relative transcriptional orientation of genes in the 3p24.2 locus (+ plus or - minus DNA strand) are 
shown with respect to the centromere. The genes located at 5'- and 3'-side of the THRB as well as the genes positioned at least 
in part inside the THRB sequence (intra-THRB genes) are highlighted by three coloured rectangles. The diagram was drawn on 
the basis of the standard ideogram taken from the NCBI Map Viewer and NCBI Human Genome Resources. 
 
This gene may function as a tumor suppressor and 
disturbances of the THRB expression are frequent 
findings in various cancers. However, the genomic 
actions of the nuclear receptor can interface with 
nongenomically initiated and TRβ -mediated effects 
of thyroid hormone on angiogenesis and cancer cell 
proliferation (Davis et al., 2009; Puzianowska-
Kuznicka et al., 2013). 
DNA/RNA 
The human THRB gene spans a region of 376609 
bp and is divided into 20 different exons inlcuding 
16 separated by large introns which may give rise 
to 19 various TRβ1 transcripts mostly differing in 5' 
untranslated region (5'UTR), 1 truncated variant 
TRβ4 (TRβ1 isoform) and 1 TRβ2 transcript with 
differential promoter usage (see diagram 2 and 3). 
Note that several sense and antisense non-TRβ  
transcripts were shown to be expressed in the 
THRB locus, in which may affect the expression of 
the thyroid hormone receptors (see diagram 2). The 
THRB gene is one of two thyroid hormone receptor 
genes in the human genome located on 
chromosome 3. The other gene, THRA located on 
chromosome 17, encodes the related thyroid 
hormone receptors TRα1, TRα2 and TR∆α1 (p28 
and p43). These genes were initially identified by 
their homology to the avian retroviral oncogene v-
erbA encoding a mutated variant of chicken TRα1. 
Description 
According to the NCBI Gene, the THRB maps to 
NC_000003.11 (24158644..24536772, 
complement) and spans a region over 376 kilo 
bases. Within the sequence, some other 
transcriptionally active genes have been identified 
(see diagram 1 and 2). 
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Diagram 2. Human THRB Gene Structure, a transcript and protein. Multiple transcript variants and 3 protein isoforms (TRβ1 
TRβ2 and truncated variant TRβ4) are generated by transcription of pre-mRNA using two THRB promoters (P1 and P2 located 
between exon 4 and 5), alternative splicing of exons marked with numbers 1-10 (horizontal bars) and separated by large introns 
(shown by distances between exons) as well as protein translation, which is differentially regulated by the 5'UTR variants. A. 
Genes localized within the THRB sequence are marked with orange or blue arrows. The orange one (THRB-IT1, THRB intronic 
transcript 1) is transcribed in the same orientation (-) to the THRB, whereas blue arrows indicate the genes in opposite 
transcriptional orientation (+): THRB-AS1, RPL31P20, LOC101927854, and two transcript variants (GeneBank: CB994391.1, 
AW950510.1) described in NR1D2 gene locus (see local order). Expression of the genes may result in production of long 
naturally occurring antisense transcripts (long NATs) that may bind complementary target strands of THRB DNA or newly 
synthesized pre-mRNA. These sense-antisense pairs may affect the expression of the THRB gene (for more details see diagram 
1). Large CpG islands identified as methylated within THRB sequence in human cerebellum, sperm and bone marrow cells are 
marked with small green ovals on double stranded DNA, whereas the green/orange ovals represent CpG islands identified as 
methylated in human colon mucosa and colorectal tumor (drawn on the basis of the NCBI Epigenomics database). B. An 
example of the multiple mRNA variants, wherein blue boxes represent alternatively spliced exons of 5' untranslated region 
(5'UTR), red - protein coding sequence, green - TRβ1 3'UTR (exon 10). C. One of two TRβ proteins (here TRβ1) and its 
functional domains: N-terminal AF1 domain (A/B), DNA binding domain (C), hinge region (D), ligand (T3) binding domain (E) and 
C-terminal AF2 domain (F), all presented in the context of subsequent amino acids (aa) encoded by the TRβ1 mRNA (CDS). 
Amino acid ranges of the NCBI reference conserved domains: C and E are indicated by gray arrows. For protein function see the 
text below. 
 
Two precursor mRNA (pre-mRNA) are transcribed 
using two THRB promoters: P1 (GeneBank: 
S37458.1), updated according to the sequence of 
chromosome 3 genomic contig (GenBank: 
NT_022517.18) allowing for expression of TRβ1 
and P2 promoter of TRβ2 isoform (see diagram 3), 
located between exon 4 and 5 (GeneBank: 
NG_009159.1; 330058..334363), however the 
sequence range of P2 has not been exactly 
established.  
The THRB gene consists of 20 different exons 
including 16 separated by large introns.  
The exons are described in details above (see  
 
diagram 3).  
The alternative TRβ1 splicing results in expression 
of multiple mRNAs encoding the same protein, 
however its translation is differentially regulated by 
the 5'UTR variants.  
These transcripts consist of 10 - 14 different exons 
forming a 5'UTR region (exons 1, 2 and the 
beginning of exon 3), protein coding region (the 
end of exon 3, 4-9, first 242nt of exon 10) and long 
3'UTR (last part of exon 10) (Frankton et al., 2004). 
The exons 5-10 are common to the most of 
transcripts including TRβ2 mRNA that contains one 
more, first exon named "a" (see diagram 2 and 3).  
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Diagram 3. THRB exons distribution and alternatively spliced 5'UTR variants of TRβ1 TRβ2 and TRβ4 mRNAs. At least 19 
mRNA variants of TRβ1 and one of TRβ2 are synthesized using two THRB promoters: P1 and internal promoter P2 located 
between exon 4 and 5. The human variant TRβ4 is a carboxyl-terminal splicing variant of TRβ1 (using P1 promoter), which 
contains a stop codon due to the presence of a 137-bp insertion located between exon 7 and 8.The third known, non-functional 
in humans promoter (P3) is shown as well. This locus is located upstream of the exon 5 but downstream of the P2 promoter and 
allows for transcription of two additional isoforms: TRβ3 and TR∆β3, expressed ubiquitously only in rats, however, the regulatory 
elements present in this region may interfere with transcription of the TRβ2 in humans. The mRNA variants are shown in the 
context of alternative and constitutive exons and their distribution within the DNA sequence. Blue boxes represent alternatively 
spliced exons of 5' untranslated region (5'UTR), red - protein coding sequence, green -3' untranslated region (3'UTR, the longest 
3' part of exon 10). Most of exons are separated by large introns, which are marked at the beginning and the end by numbers 
representing their relative position on DNA. The diagram shows a region of 378,609 kb (24133709..24516317; Ref.seq. : 
NC_000003.11). The exact size (nt) of each exon is given below the exon boxes. The 5'UTR region of TRβ1 may include up to 
10 alternatively spliced exons and 44 bp of exon 3, whereas 5'UTR of TRβ2 contains only 105 of 434 nucleotides of exon 1 
named "a". The exons 5-10 are mostly constitutive and common with almost all transcripts including TRβ2 mRNA. The most of 
identified transcript variants (shown at the middle of the diagram) differ only in the 5' untranslated region, which can influence the 
protein synthesis. 3'UTR variant H lacks 123 nucleotides (miRHS fragment). This region contains a putative binding site for 
miRNA-204, located between nucleotides 2313-2319 of TRβ 3'UTR. Variants IVS4A and IVS4B contain alternatively spliced 
exons of 5'UTR, exon 3, 4 and a fragment of intron with a stop codon located downstream of the exon 4 that may result in 
translation of truncated protein (28 amino acids) of unknown function. The GeneBank accession numbers for each reference 
sequence are given next to the adjacent transcript variant. 
 
The variant TRβ4 contains additional 137-bp 
insertion (exon) between exons 7th and 8th shown in 
diagram 3 (intron 5th according to Tagami et al., 
2010) that results in synthesis of a truncated protein 
lacking the ligand binding domain. 
This isoform may modulate T3 action as an 
endogenous antagonist (according to Tagami et al., 
2010). 
The multiple 5'UTR splice variants of the TRβ1 can 
differently regulate translation of the TRβ1 coding 
sequence. The 5'UTRs vary in length, GC-content, 
secondary structures, number of upstream open  
 
reading frames (uORFs) and internal ribosome 
entry site (IRES) predicted in the variant A 
(GeneBank: AY286465.1). These regulatory 
sequences may be organized in secondary and 
tertiary RNA structures that are recognized by 
trans-acting factors such as protein translation 
factors and naturally occurring small RNAs. 
Moreover, the most of TRβ mRNA variants contain 
long 3'UTR (see diagram 3) with multiple 
microRNA binding sites that may affect the 
expression of these receptors. Disturbances in the 
expression of the TRβ mRNA variants have been  
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reported in various cancers. Some of the 
disturbances seem to be a cancer specific. For 
example, the loss of transcript variants F1 
(GQ456950) and IVS4B (GQ919288.1) has been 
observed in clear cell renal cell cancer (ccRCC). In 
the same tissues, over 70% reduction in TRβ1 
mRNA (coding sequence) has been reported. 
Simultaneously, expression of 5'UTR variants A 
and F (AY286470.1) has been reduced in ccRCC 
by 75% and 62%, respectively, compared to control 
samples (Master et al., 2010). 
Note also that several sense and antisense non-TRβ 
transcripts have been shown to be expressed in the 
THRB locus, in which may affect the expression of 
the thyroid hormone receptors (see diagram 2 and 
3). 
Transcription 
Two precursor mRNAs (transcribed from two 
different promoters of the THRB) undergo 
extensive co- and post-transcriptional modification 
in the nucleus that includes tissue specific, 
alternative splicing of the pre-mRNAs. 
Pseudogene 
No pseudogene has been reported for the THRB 
gene. Nevertheless, the THRB may be regulated by 
pseudogenes identified within the THRB gene 
sequence or in the same locus (see diagram 1 and 
2). The pseudogenes may produce long naturally 
occurring antisense transcripts (cis-NATs) forming 
sense-antisense pairs (see Homology). These sense-
antisense pairs may activate numerous mechanisms, 
similar to those observed in a pseudogene-mediated 
regulation of a target gene via pseudogene-derived 
small interfering RNAs or on the level of RNA-
directed DNA methylation, pre-mRNA 
transcription, alternative splicing as well as RNA 
editing, transport and localized protein translation. 
However, this regulation remains to be established 
for the THRB gene. 
Protein 
Note 
The human THRB encodes three protein isoforms, 
the TRβ1 and TRβ2 that are T3-dependent 
receptors mediating genomic and nongenomic 
actions of the thyroid hormone, and TRβ4 isoform, 
which is a carboxyl-terminal splicing variant of 
TRβ1 that lacks the ligand binding domain and 
thus, may modulate T3 action as an endogenous 
antagonist in the tissue or cellular context (Tagami 
et al., 2011). The TRβ proteins are implicated in 
regulation of transcription of target genes and 
control key cellular processes including 
differentiation, proliferation, apoptosis and  
 
 
metabolism. 
Description 
There are three human TRβ isoforms TRβ1, TRβ2 
and TRβ4, which are differentially expressed in 
various tissues. The TRβ1 and TRβ2 receptors have 
the typical domain structure of a nuclear receptor 
with an N-terminal domain (A/B), central DNA 
binding domain (C) consisting of a double C4-type 
zinc fingers, hinge region (D), C-terminal ligand 
binding domain (E), and AF2 domain (F). These 
receptors have a variable N-terminal domain (A/B) 
that differs between TRβ1 and TRβ1 isoforms (see 
diagram 4). The N-terminus is responsible for 
cofactor and regulatory protein binding, T3-
independent transactivation, receptor dimerization 
and DNA recognition. Local dimerization sites 
have been found in domain C, E, corepressor 
interaction sites in domain D, E and coactivator 
interaction sites in domain A/B, E and F. The hinge 
region (D) is also found to be required for TRβ 
dependent suppression of ras-mediated responses. 
The TRβ1 can bind to target DNA sites regardless 
of T3 binding status as a homodimer or heterodimer 
with retinoid X receptors (RXR) or as a monomer 
(more weakly).  
TRβ can bind to DNA in the absence of ligand and 
therefore is thought to have the potential to mediate 
both T3-dependent and T3-independent regulation 
of target gene transcription. The protein 
phosphorylation has been shown to enhance its 
cytoplasmic-nuclear import (Maruvada et al., 
2003). Phosphorylated T3 receptors can exhibit 
increased TRE binding as a homodimer, but not as 
heterodimer or monomer. Moreover, integrin-
mediated non-genomic action of T4 (Davis et al., 
2009) may result in phosphorylation of TRβ1 
Ser142 leading to dissociation of the corepressors 
and transactivation of target genes (Davis et al., 
2000). In case of typical positively regulated genes 
such as DIO1 encoding iodothyronine deiodinase 
type I and GH1 of human growth hormone 1, T3 
binding stimulates a conformational changes in the 
TRβ allowing for dissociation of corepressors 
followed by recruitment of coactivators to form an 
activating complex stimulating the transcription. 
There is also identified a group of negatively 
regulated genes that includes hypothalamic 
thyrotropin-releasing hormone (TRH) and pituitary 
thyroid stimulating hormone (TSH) encoded by 
TSHB and controlling the hypothalamic-pituitary 
thyroid (HPT) axis. In this regulation liganded 
nuclear receptors down-regulate target gene 
transcription, with the cooperative binding of 
various transcription factors to multiple regulatory 
elements on DNA (for more see genomic actions of 
T3 mediated by TRβ receptors). 
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Diagram 4. Structural and functional organization of TRβ proteins. A. Three thyroid hormone receptor beta isoforms: TRβ1 
TRβ2 and truncated variant TRβ4 are encoded by the human THRB gene. Functional domains of the transcription factors are 
divided as follows: N-terminal AF1 domain (A/B) responsible for hormone independent transactivation and regulatory proteins 
binding; DNA binding domain (C) containing two C4-type zinc fingers; hinge region (D) with nuclear localization signal allowing 
for nuclear transport (regardless of T3 binding status); ligand (T3) binding domain (E) that allows for dimerization (usually with 
RXRα receptor) as well; C-terminal AF2 domain responsible for T3-dependent transactivation of target genes (F). The domains E 
and F bind corepressors or coactivators regulating the activity of the TRβ receptors. The TRβ1 and TRβ2 are functional 
receptors of T3 differing only in the length of the A/B domain, however their expression is tissue specific. The human variant 
TRβ4 is a truncated variant of TRβ1, lacks T3 -binding ability and acts as an endogenous dominant-negative isoform. B. 
Crystallographic structure of heterodimer formed by the human thyroid hormone receptor DNA-binding domain and retinoid X 
receptor DNA-binding domain (rainbow colored) complexed with double strained DNA (green). Zinc atoms are depicted as 
blue/pink dots. The structure is presented in the context of the thyroid hormone response elements (TREs) that are specific DNA 
sequences recognized by the receptors. The TRE-DR4 is formed by consensus core recognition motif (AGGTCA) that is 
positioned as direct repeats separated by 4 nucleotides. The other TREs including palindrome (TRE-P0) or inverted palindrome 
(TRE-IP6) are shown as well. C. Crystallographic structure of the ligand binding domain of the human thyroid hormone (T3) 
receptor beta (rainbow colored, N-terminus in blue, C-terminus in red) complexed with triiodothyronine (T3). Binding of 
unliganded receptor alone to DNA usually leads to recruitment of corepressors (CoR) and inhibition of target gene basal 
transcription, whereas binding of T3 in hormone binding pocket is thought to cause conformational changes leading to 
dissociation of corepressors followed by recruitment of coactivators (CoA) and activation of the transcription. Mutations in C-
terminal α-helix domain (red) that can close the hormone binding pocket and the α-helix shown here in green are frequent 
findings in the thyroid hormone resistance syndromes (RTHs) and cancers. The conserved domains were visualized using 
PyMOL 1.3 Molecular Graphics System, on the basis of crystallographic structure files (PDB: 2NLL, 1XZX) of The RCSB Protein 
Data Bank and The NCBI Conserved Domains Database (CDD, ref.c.d.: cd06961 NR_DBD_TR, cd06935: NR_LBD_TR). 
 
The TRβ4 is a C-terminal splicing variant of TRβ1 
which contains a stop codon in an 137-bp insertion 
(exon) insertion that results in synthesis of a 
truncated protein lacking the ligand binding domain 
(see diagram 4). The TRβ4 contains full A/B, C, D 
domain of TRβ1 and a fragment of domain E (is 
identical for the first 246 amino acids) but the 
carboxyl-terminal 215 amino acids of TRβ1 are 
replaced by an entirely distinct sequence of 13 
residues, which results from an insertion (see 
RNA). Therefore, this truncated protein is unable to 
bind thyroid hormone, thus may modulate T3 action 
as an endogenous antagonist in the tissue or cellular 
context. The TRβ4 cannot mediate T3-dependent 
gene regulation but may inhibit the negative 
regulation of TSH mediated by TRβ1 or TRβ2, that 
was shown in TSA-201 cells, a clone of human 
embryonic kidney 293 cells (according to Tagami et 
al., 2010 and Tagami et al., 2011). These findings 
are consistent with current model for T3-dependent 
negative regulation of TSHB gene (see genomic 
actions below). 
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The levels of TRβ proteins depend on the protein 
stability and transcription/translation efficiency that 
is tissue specific and differentially regulated in 
various mRNA variants. The frequently reported 
lack of correlation between the mRNA and protein 
suggests that apart from transcriptional control the 
expression of TRβ receptors is accurately controlled 
at the level of translation. In fact, multiple 5'UTR 
variants of TRβ1 have been shown in vitro to 
differentially regulate the protein translation. The 
major renal TRβ1 transcript contains a 5'UTR 
relevant to variant A (GeneBank: AY286465.1). 
Analysis of the effects of 5'UTR variants on protein 
expression in JEG-3 choriocarcinoma cells 
(Francton et al., 2004) and Caki-2 renal cancer cells 
(Master et al., 2010) indicated that the weakly 
folded variant A permitted also the highest level of 
protein expression. In contrast, the strongly folded 
5'UTR variants: F (AY286470.1) or F1 
(GQ456950) was identified to be transcribed and 
translated at the lowest levels. Although, structured 
5'UTR such as variant F treated in vitro with a 
trans-acting factor (an antisense oligonucleotide) 
significantly up-regulated the translation efficiency 
of a downstream sequence up to the level of the 
variant A. This may estimate the potential of the 
5'UTR-mediated translational control during 
expression of TRβ receptors. The translation of the 
TRβ can be also modulated by multiple regulatory 
ORFs that exist upstream of the primary ORF. On 
the other side, the protein synthesis may be 
controlled by long TRβ 3'UTR through binding of 
various microRNAs including miR-21 and miR-
146a. The microRNA can trigger the RNA 
interference (RNAi) phenomenon that may lead to 
translational repression or even degradation of TRβ 
mRNAs (Jazdzewski et al., 2011). Since UTR-
mediated translation initiation is a key rate-limiting 
phase affecting efficiency of the protein synthesis, 
the translational control mediated by the multiple 
UTR variants is emerging to be a major regulator of 
the final protein levels in cells. The TRβ receptors 
have been also reported to be affected by aberrant 
promoter methylation, alternative splicing and 
impaired cell signaling. 
Expression 
The thyroid hormone receptor isoforms are 
products of both the THRB and THRA genes. 
During development, TRβ and TRα isoforms are 
differentially expressed in a temporospatial and 
tissue-specific patterns and in adult tissues are 
present in distinct ratios (Williams, 2000; Francton 
et al., 2004). 
TRβ1 is widely expressed in all human tissues, but 
is prominent in brain, thyroid, kidney and liver. 
TRβ1 controls liver and kidney metabolism and 
mediates cholesterol lowering effects of thyroid 
hormones. Both the TRβ1 and TRβ2 are essential 
for regulation of thyroid hormone levels through 
the hypothalamic-pituitary-thyroid (HPT) axis, a 
negative feedback loop, which includes auto-
control of hypothalamic Thyrotropin-Releasing 
Hormone (TRH) and pituitary Thyroid-Stimulating 
Hormone (TSH) by the thyroid hormones (TH). In 
this regulation, the TRβ receptors mediate TRH- 
and TSH- lowering effects of TH. 
TRβ2 is restricted to the hypothalamus, anterior 
pituitary, developing brain, cochlea (inner ear) and 
retina, wherein TRβ2 alone is crucial for 
development of mid-wavelength (MW) cones 
photoreceptors, which play a significant role in 
circadian clock light entrainment and in phase 
shifting of the circadian oscillator (Dkhissi-
Benyahya et al., 2007). This isoform is therefore 
important for visual and auditory function. Down 
regulation of hypothalamic TRH is TRβ2 specific. 
TRβ2 mRNA has been also identified in situ in 
human chondrocytes and osteoclasts (Abu et al., 
2000). 
TRβ4 isoform is expressed in various human tissues 
but is highly abundant in testis and skeletal muscle. 
This isoform lacks T3 -binding domain and may act 
as a dominant-negative protein. It has been 
identified in a TSH-secreting pituitary adenoma 
(TSHoma) as well (Tagami et al., 2011). 
In contrast, TRα mediates T3 actions during 
development of heart, bone, intestinal and is 
responsible for body temperature and basal heart 
rate in adults. TRα1 and TRα2 isoforms are highly 
expressed in the brain, with lower abundance in the 
kidneys, skeletal muscle, lungs, heart, and testes. 
The TRα1, TRβ1, and TRβ2 isoforms can bind 
DNA and T3 acting as functional thyroid hormone 
receptors, whereas TRα2 and TRα3 do not bind T3 
due to the presence of the longer AF2 (F) domain, 
and act as antagonists. There are some truncated 
isomers of TRα with specific mitochondrial 
functions (p28, p43) or may act as dominant-
negative receptors (TR∆α1, TR∆α2). There are also 
known two additional TRβ receptors expressing 
only in rats: functional T3 receptor - TRβ3 and its 
dominant negative isoform -TR∆β3 (Williams et 
al., 2000). 
Both, TRβ and TRα isoforms are involved in 
circadian cycle that was demonstrated in an in vivo 
mouse model, in different metabolic tissues 
including white adipose tissue (WAT), brown 
adipose tissue (BAT), liver, and skeletal muscle 
(Yang et al., 2007). While TH levels are generally 
constant, the TRβ and TRα along with their key 
target genes dramatically cycle in a coordinated 
manner that is in agreement with known cyclic 
behaviour of lipid and glucose metabolism. TRβ 
has been shown to cycle in WAT, whereas TRα in 
WAT, BAT and liver. Analysis of TRβ mRNA 
expression revealed a unique rhythmic pattern in 
which their transcripts spike at ZT4 (Zeitgeber 
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time, 4h after lights were turned on) followed by a 
precipitous decline in the next 4h, and remain at 
low levels through the rest of the day. Interestingly, 
mRNA levels of heme-liganded nuclear receptor 
Rev-erbβ encoded by NR1D2 gene, which may 
interact with THRB expression (see diagram 1 and 
2), dramatically cycle in the all examined metabolic 
tissues.  
Although precisely how the circadian clock acts to 
control metabolic rhythms is not clear, it is known 
that the ratio of TRα1/TRα2 isoforms is closely 
determined by co-expression of Rev-erbα (NR1D1) 
- a key component of the circadian core oscillator 
complex.  
The Rev-erbα represses the expression of BMAL 
changing the expression of other genes of the cycle 
including CLOCK, PER1, PER2, PER3 and 
cryptochrome genes CRY1 and CRY2 responsible 
for blue light photoreceptor activity (see specific 
functions of TRβ2).  
The cell -autonomous feedback loop allows for 
cyclic expression of these oscillator genes at 
various phases with the same period length of 
approximately 24r (Zhang et al., 2009).  
All this findings suggest a role for TRβ, TRα and 
heme receptors (Rev-erbβ, α) in coupling the 
peripheral circadian rhythm to divergent metabolic 
outputs.  
Since the expression of TRβ is prominent in brain 
and metabolic tissues, it is expected that these 
receptors may serve peripheral clock input 
pathways that can integrate signals from the light-
sensing central clock in the suprachiasmatic nuclei 
(SCN) and other cues including xenobiotic 
metabolism pathways.  
Interplay between the circadian clock and TH 
receptors may be a part of a large -scale signaling 
network that links biological timing to metabolic 
physiology (Yang et al., 2006). 
Localisation 
Subcellular localization and changes in expression 
of TRβ receptors can vary depending on the cell 
cycle phase, cell density, cellular stress, signaling 
events, tissue types, metabolic rate or even 
circadian cycle (Maruvada et al., 2003). 
Typically, TRβ1 and TRβ2 isoforms are 
predominantly localized to the nucleus and retained 
in the nucleus regardless of the ligand binding 
status (in the absence and presence of T3). 
However, T3 can induce a nuclear reorganization of 
TRβ receptors. The nuclear localization is essential 
for TRβ-mediated genomic actions of T3. In 
standard conditions, a minor fraction of TRβ 
proteins resides in the cytoplasm, wherein the 
receptors are thought to be mediators of 
nongenomic actions of thyroid hormone (TH). The 
cytoplasmic-nuclear shuttling is facilitated by the 
presence of a nuclear localization signal (NLS) in 
the TRβ hinge region (D). The TRβ nuclear import 
is ATP-dependent and can be regulated by 
nongenomic actions of TH through 1) T4-
dependent activation of plasma membrane integrin 
αvβ3 (Davis et al., 2009) followed by activation of 
downstream pathways leading to phosphorylation 
of ERK1/ERK2 and TRβ1 proteins and/or 2) via 
T3-dependent formation of cytoplasmic TRβ1 
complexes with p85 subunit of PI3K that may 
activate downstream pathways. The TRβ complexes 
with p85, ERK1/2 or nuclear receptor coactivators 
may facilitate nuclear import as well. TRβ rapidly 
shuttles between the nuclear and the cytoplasmic 
compartments. Energy-dependent blockade (ATP 
depletion) enhances TRβ nuclear export to 
cytoplasm. Nevertheless, coexpression of nuclear 
corepressors (NCoRs) and/or retinoid X receptors 
(RXRs) can markedly decrease the shuttling by 
maintaining unliganded TRβ within the nucleus. A 
TRβ mutant defective in DNA binding has a 
slightly altered nuclear-cytoplasmic distribution 
when compared with wild-type TRβ. TRβ mutants 
that abrogate its interaction with the NCoRs 
accumulates within the cytoplasm due to an 
increase in the rate of nuclear export when 
compared with nuclear import. Nuclear-cytoplasmic 
shuttling has been proposed as a mechanism for 
modulating TRβ-mediated regulation of 
transcription (Maruvada et al., 2003). 
Subcellular localization of TRβ4 is unknown; 
however the lack of T3 binding domain might 
suggest an altered nuclear/cytoplasmic distribution. 
Function 
TRβ proteins are high affinity receptors for thyroid 
hormone (TH) functioning as ligand-dependent 
(T3) and sequence-specific DNA binding (TRE) 
transcription factors (see genomic actions below) 
that regulate expression of target genes affecting 
cell growth, development, proliferation, 
differentiation, apoptosis, organ morphogenesis, 
heart rate, body fat distribution, bone density. These 
receptors are required for the development of the 
auditory system and of the cone photoreceptors that 
mediate colour visual function. TRβ1 isoform is 
expressed in most tissues, whereas TRβ2 is 
restricted to the hypothalamus, pituitary, cochlea, 
and retina that may indicate the functional 
specificity of the isoforms. 
The TRβ1 control the major responses of the liver 
and kidney to T3 and play a critical role in 
mediating changes in metabolism and 
thermogenesis. The T3 receptors are able to 
increase metabolic rate by accelerating fuel 
oxidation in most of tissues wherein they may 
activate lipolysis, glucose metabolism and protein 
synthesis. 
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Diagram 5. Schematic representation of selected TRβ-mediated, genomic and non-genomic actions of TH. The thyroid 
gland, in response to TSH, produces thyroxine (T4) and 3,5,3'-triiodo-L-thyronine (T3), however greater amounts of T4 are 
produced than T3. The thyroid hormone (TH) in the circulation are bound to protein -transporters that deliver TH to peripheral 
tissues wherein TH triggers TRβ-mediated effects including negative regulation of the hypothalamic-pituitary thyroid (HPT) axis. 
For genomic actions, T4 needs to be converted to T3 by DIO1 or DIO2 present in peripheral tissues such as liver, brain or 
kidney. G. Classical model of TH actions in the nucleus. The model is based on the action of triiodothryonine (T3, ligand) on 
positively regulated genes. The regulation requires: thyroid hormone response elements (TREs) on specific genes, complexes of 
nuclear TH receptors (TRs) and T3, coactivator (CoA) or corepressor (CoR) nucleoproteins, and histone acetyl transferase 
(HAT) or deacetylase (HDAC). G1. Ligand-bound state. TRβ can bind to DNA as heterodimer with RXR and regardless of T3 
binding status. However, T3 binding results in release of corepressor complex, recruitment of a coactivator complex (e.g. SRC-1, 
CBP, p300, pCAF, TRAP-DRIP, mediator/integrator components) and HAT. The HAT activity allows for reducing chromatin 
compaction and permitting general transcriptional factors (GTFs) to interact with DNA and activate transcription of a target gene. 
G2. Ligand-free state. In absence of ligand, the unliganded TH receptors interact with a copressor complex that may include 
NCoR, SMRT and histone deacetylase 1 (HDAC1). The recruitment of this complex may result in reduced histone acetylation 
(shown as Ac), which in turn compacts chromatin structure and represses the gene transcription. The transactivation domain of 
the T3-free receptor, as a heterodimer with RXR, assumes a conformation that promotes interaction with a group of 
transcriptional corepressor molecules. N. Nongenomic actions of TH mediated by TRβ1. These actions are fast (within 10-40 
min), frequently reported to result in pro-proliferative, pro-angiogenic, anti-apoptotic effects. These actions may be simplified into 
two main signaling cascades: N4) extracellular-T4/ αvβ3-integrin/ PLC/ PKCα/ ERK1/2/ TRβ1-Ser142 phosphorylation that among 
others can result in specific gene transactivation or transrepression (N4); N1) cytoplasmic-T3/ TRβ1/ CSH2-p85α-p110(PI3K)/ 
Akt/ mTOR phosphorylation leading to transcription of PI3K-specific genes such as HIF1A and GLUT1 (SLC2A1) (N1, N1b, N1c). 
Specific inhibitors of these pathways are shown in red font. N1. Nongenomic effects of T3 may be initiated in cytoplasm by TRβ-
dependent activation of PI3K that leads to sequential activation of Akt/PKB/mTOR-p70S6K as well as the other mTOR targets 
including upregulation PI3K-dependent genes. A fraction of TRβ1 present in the cytosol forms a complex with p85α subunit 
(regulatory subunit of PI3K) in a ligand independent manner that activate PI3K. The kinase generates phosphatidyl inositol-3,4,5-
triphosphate (PIP3) from PtdIns(4,5)P2 (PIP2) activating downstream pathways via Akt/PKB (N1b) or through phosphorylation of 
the TRβ1 followed by its nuclear import. Wild-type TRβ1 competes with corepressor NCoR or mutant TRβPV for binding to the 
CSH2 domain of p85α (N1c). This PI3K activity is blocked by specific inhibitors such as Wortmannin or LY294002. N2. Signal 
transduction via plasma membrane receptor αvβ3 by T3 binding to the extracellular part of the receptor. The binding domain 
includes a receptor site (S1) exclusively for T3 that activates phosphatidylinositol 3-kinase (PI3K) and leads to shuttling of 
cytoplasmic TRβ to the nucleus followed by transcription of specific target genes such as HIF1A. N3. Cytosolic TRβ1 and PI3K 
are involved in T3-stimulated activation of Na+/K+-ATPase and other features of the sodium pump (gene expression, plasma 
membrane insertion). Besides, TH is known through αvβ3 to modulate the activity of several other ion transport systems 
including Na+/H+ exchanger NHE (SLC9C1). N4. T4-induced activation of ERK1/2 through plasma membrane receptor αvβ3 (site 
S2). This action is relevant to: intracellular trafficking of proteins, including TRβ1, serine phosphorylation (P) and acetylation (Ac) 
of this nuclear receptor, assembly within the nucleus of complexes of coactivators or corepressors and transcription of specific 
genes, including that for TRβ1. The action includes T4 binding to the extracellular part of the receptor, activation of PLC, PKC, 
ERK1/2 (MAPK) pathway, phosphorylation on TRβ (Ser142), derepression and enhancement of transcription. Among the 
consequences of ERK1/2 activation are specific serine phosphorylation of the cytoplasmic/nuclear TRβ1 (Ser142) and estrogene 
receptor α ERα, phosphorylation of signal transducers and activators of transcription STAT1α, STAT3 as well as p53, wich were 
found to be co-immunoprecipitated with the activated ERK1/2. Cytoplasmic fraction of TRβ are shuttled to the nucleus, wherein 
the proteins are transcriptionally active and can modulate the actions of certain cytokines and growth factors including those 
involved in tumor cell proliferation and on angiogenesis. TETRAC is an analog of T4 that can inhibit this nongenomic action of 
T4, however, showing thyromimetic properties it can also affect gene expression in the cells, regulating transcription of target 
genes such as THBS1, CASP2 and CBY1. For details see text. 
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TH receptors are responsible for T3-dependent 
homeostasis and maintenance of a steady body 
temperature that is realized via an auto-regulatory 
negative feedback loop controlling the 
hypothalamic-pituitary thyroid (HPT) axis. Its 
regulation is mainly determined by local T3 
concentration in the anterior pituitary as well as 
paraventricular nucleus (PVN) of the hypothalamus 
wherein low levels of T3 abolish TRβ-mediated 
transcriptional repression of pituitary thyroid-
stimulating hormone (TSH) promoter and 
hypothalamic thyrotropin-releasing hormone (TRH) 
promoter. However, the local tissue T3-levels are 
dependent on the availibility of circulating thyroid 
prohormone - thyroxine (T4), its intracellular 
transport and cytoplasmic T3 production, catalyzed 
by iodothyronine deiodinases. Since TRs can form 
heteroduplexes with retinoid X receptors, TH is 
found to modulate the skin response to retinoids. 
Genomic effects of TRβ1 have been recognized as 
tumor suppressive and disturbances of the TRβ1 
expression have been found in different cancers 
(Martínez-Iglesias et al., 2009b; Kim at al., 2013). 
Description 
TRβ is involved in many processes that compose 
thyroid hormone (TH) actions and gene expression. 
This T3-dependent receptor act as a transcription 
factor regulating expression of genes involved in 
the cell cycle progression, differentiation, apoptosis 
and cellular metabolic rate. TH exerts a pleiotropic 
effect on development and homeostasis. This effect 
results from genomic and nongenomic TH actions 
mediated by both, the TRβ and TRα receptors 
(TRs) that regulate hundreds of genes responding to 
T3-liganded or unliganded receptors. A large 
number of genes have been identified to respond to 
T3 stimulation (~10% of all expressed genes) and 
the divergence between T3-treated and untreated 
cells can grow rapidly over time. The initial studies 
of TRs actions revealed near complete overlaps in 
their effects (TRα and TRβ can regulate similar 
gene sets). However, gene-specific differential TRα 
and TRβ actions are reported as well. These 
differences appear to result from the 1) differences 
in tissue-specific expression patterns, 2) diurnal 
rhythm (see expression and specific functions), 3) 
various time-courses of actions with different 
kinetics 4) target gene-specific variations in pattern 
of response to T3 concentration. For instance, TRβ 
has been shown to exhibit gene-specific 
requirements for higher T3 levels (compared to 
TRα) for regulation of HR, MYH6, ALPI and 
FURIN genes, whereas HIF1A is identified to have 
lower T3 requirements during TRβ-mediated 
regulation. ANGPTL4 encoding a PPARG 
angiopoietin related protein is a verified in parental 
HepG2 cells direct TRβ target. Prolonged T3 
treatment selectively augments TRβ action in the 
context of the TRβ-dependent genes. Moreover, 
several T4- and T3- analogues (see ligands) have 
been also reported to induce TRβ-specific response. 
Genomic and nongenomic actions 
Genomic actions of TRβ are initiated with nuclear 
translocation of the newly synthesized receptors 
(Maruvada et al., 2003) that is facilitated by nuclear 
localization signal (NLS) found in the hinge region 
(D) of the receptors (see diagram 2 and 3). The TRβ 
proteins are classified as type II nuclear receptors, 
which are retained in the nucleus regardless of the 
ligand binding status (free or occupied by T3) and 
bind to TREs (thyroid hormone response elements) 
as heterodimers with retinoid X receptors (RXR), 
rarely as homodimers or monomers. The TREs are 
specific DNA sequences of the consensus core 
recognition motif AGGTCA, AGGACA or 
(A/G)GGT(C/A/G)A hexamers (half-site →), in 
which two or more motifs are positioned as direct 
repeats separated by 4, 0 or 6-nucleotide: (TRE-
DR4, →n4→), palindromes (TRE-P0, →←) or 
inverted palindromes (TRE-IP6, →n6←). The 
analysis of the response elements formed by direct 
repeats of the half-sites demonstrated that a spacer 
of 4-nucleotides can provide maximal 
transactivation by TRβ in TRβ-RXR heterodimers 
but the transactivation efficiency may depends on 
sequence context of the TRE, tissue specific trans-
acting factors and ligand concentration. It has been 
also shown that for an efficient genomic action of 
the heterodimers, the presence of TRβ and RXR 
ligands: triiodothyronine (T3) and 9-cis retinoic 
acid (9-cis RA) may be necessary. However 
synergistic effects of the RXR ligand and T3 on the 
heterodimers (RXR/TR)-mediated transcription 
have been reported for specific promoters, the other 
studies suggest that RXR ligands may inhibit T3-
dependent transactivation, possibly by promoting 
the formation of RXR homodimers. The biological 
effects of TRE binding by the unoccupied versus 
the T3-occupied receptor are quite different. In 
many cases, binding of the unliganded or 
antagonist-liganded receptor alone to DNA may 
lead to repression of transcription, whereas binding 
of the agonist (T3)- liganded receptor complex 
activates transcription. However, the receptor 
activity is mainly regulated by ligand-dependent 
interactions with corepressor (CoR) and coactivator 
(CoA) proteins. In the absence of ligand (T3), the 
TRβ receptors are often complexed with 
corepressor proteins (CoRs, NCoR, SMRT) and 
histone deacetylases (HDACs) allowing the 
histones to wrap the DNA more tightly. T3 binding 
to these nuclear receptors causes conformational 
changes leading to dissociation of corepressors and 
recruitment of coactivator proteins (CoAs, SRC3, 
CBP, p300, pCAF), as well as mediators (TRAP-
DRIP multi-subunit complex) that are thought to 
target the entire complex to a liganded receptor 
through a single subunit, TRAP220. The thyroid 
THRB (Thyroid Hormone Receptor, Beta) Master A, Nauman A 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(6) 410 
hormone (TH) receptors, similarly as vitamin D3 
receptors (VDRs), and peroxisome proliferator-
activated receptors (PPAR), exhibit a strong 
activation function 2 (AF2)-dependent preference 
for receptor binding domain 2 (RBD-2) of the 
TRAP220 protein. It has been also demonstrated 
that RXR receptor (in TRβ/RXR heterodimer) 
displays a weak yet specific AF2-dependent 
preference for another TRAP220 RBD-1 domain. 
Addition of ligand for the RXR receptor (9-cis RA), 
in addition to T3 for TRβ partner, might further 
strengthen the RXR-RBD-1 interaction and 
presumably stabilize the overall association of 
TRAP220 with the heterodimer. After formation of 
the coactivator multi-subunit complex, general 
transcription factors (TAFs, TFIIA, TBP) and RNA 
polymerase II are recruited to the complex that 
initiates transcription DNA into pre-RNA. The pre-
mRNA undergoes further modifications including 
alternative splicing, mRNA editiing and translation 
into protein that may result in a change in cell 
function. The nuclear receptors including TRβ 
proteins can regulate gene expression by binding 
directly or indirectly (via other proteins) to specific 
sequences in the promoters of target genes 
(Puzianowska-Kuznicka, 2013). Apart from the 
current model of HRE/TRE - dependent 
transcriptional control, it has been proposed that 
one transcription factor may repress the activity of a 
second transcription factor through a protein-
protein interaction, without the requirement of two 
different DNA binding sites. These proteins, 
notably AP1 and NF-kB, can act by interfering with 
transcriptional complex formation in a DNA-
independent manner and may lead to 
transrepression of target gene transcription, what 
has been also shown in TRβ-mediated negative 
regulation of the hypothalamic-pituitary thyroid 
(HPT) axis. TH responsive genes can be both 
positively and negatively regulated by T3-liganded 
TRβ receptors. Iodothyronine deiodinase type I 
(DIO1) or GH1 of human growth hormone 1 are 
up-regulated in the presence of T3 (see positive 
regulation model - diagram 5). In contrast, pituitary 
TSH encoded by TSHB gene is down-regulated by 
T3 and rises during T3 deprivation. In this 
regulation, liganded nuclear receptors down-
regulate target gene transcription, with the 
cooperative binding of various transcription factors 
to multiple regulatory elements on DNA. It has 
been proposed that the negative regulation of the 
TSHB gene may require at least two response 
elements on promoter DNA (nTRE-"negative" TRE 
and GATA-RE) as well as dimerization of liganded 
TRβ with a GATA transcription factor (e.g. 
GATA2), that can repress the activity of the GATA. 
In fact, the nTRE in the promoter of TSHB gene 
contains a single half site-like sequence 
(GGGTCA). The GATA2 alone can activate TSHB 
promoter, and this activation was repressed by Zn-
finger region of liganded TRβ. Upon T3 binding, 
the T3/TRβ complex is thought to be released from 
nTRE, favoring its translocation and interaction 
with GATA-2 zinc finger region (GATA2-Zf) on 
GATA-RE located next to the nTRE. The 
T3/TRβ/GATA2-Zf/DNA complex formation is the 
principal complex responsible for the TSHB gene 
down regulation. This interaction occurs via the 
highly conserved zinc-finger in DNA binding 
domains that may resemble the trans-repression-
like mechanism in which direct binding of the 
receptor to another transcription factor occurs in a 
DNA-independent manner. In the absence of T3 
TRβ prefers nTRE element, allowing for the gene 
transcription. This negative regulation shows that 
T3 weakens TRβ binding to the regulatory element 
(nTRE) in the TSHB promoter. The displacement 
of the liganded TRβ from nTRE to another site 
(GATA-RE/GATA2-Zf) seems to be critical for the 
mechanism used by the cell for silencing the TSHB 
gene transcription (Figueira et al., 2010). Down-
regulation of hypothalamic thyrotropin-releasing 
hormone TRH gene by T3/TRβ complexes involves 
acetylation and methylation of specific residues of 
histone tails in the TRH promoter region and relies 
on changing amount of the TRβ receptors on TRH 
nTRE after T3 binding (Umezawa et al., 2009). 
Prolonged administration of T3 causes 
demethylation of specific histones and subsequently 
the release of TRβ receptors from the gene to 
suppress it. Both negative regulations may require 
T3/TRβ to be removed from its nTRE to down-
regulate the genes, although the mechanism used by 
a ligand-bound TRβ leading to repression of 
transcription is still a subject of contention. The 
classical mechanism of TRβ activity suggests that 
receptors typically complexed with RXR bind more 
strongly to DR4 in a clearly cooperative binding 
between the transcription factors and DNA (see 
diagram 5). Nevertheless, coexpression of RXR and 
TRβ2 has been also shown to slightly reduce both 
the transactivation and transrepression by liganded 
TRβ2 that may act more strongly as homodimer or 
monomer, depending on the architecture of the 
TRE. Thus, the mechanism responsible for TRβ-
mediated genomic action of T3 is still unclear. 
Several recent studies indicate that at the genomic 
level TRβ may act as a tumor suppressor. For 
instance, the gain-of-function approach by stably 
expressing TRβ in a human breast cancer cell line 
MCF-7 (MCF-7-TRβ), which normally lacks the 
TR expression, has been reported to inhibit the 
growth of the MCF-7 cell tumors in xenograft 
models (Park et al., 2013). These estrogen (E2) 
dependent cells show elevated JAK2-STAT3-cyclin 
D signal that is repressed by the TRβ expression at 
the level of transcription. Interestingly, other 
studies indicate that TH has anti-apoptotic and pro-
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proliferative effects in ERα-positive human breast 
cancer cells (Perri et al., 2013). However, these 
opposite effects are recognized as a result of the 
αvβ3 integrin -dependent nongenomic actions of 
TH (see below). 
Nongenomically initiated, TRβ -mediated thyroid 
hormone (TH) actions occur at the plasma 
membrane or in cytoplasm and may also culminate 
in complex, nucleus-mediated cellular events 
leading to the transcription of specific genes such as 
HIF1A, MCL1 or GLUT1 (Moeller et al., 2006; 
Davis et al., 2009). The nongenomic actions of TH 
can interfere with genomic effects of T3, hence, a 
clear distinction between nongenomic and genomic 
effects may no longer be practical. However, 
initiation events leading to these effects are quite 
different and may have different kinetics or timing. 
For instance, enhancement of the antiviral activity 
of interferon-γ by TH is achieved nongenomically 
and genomically by T4-dependent activation of the 
mitogen activated protein kinase /extracellular 
signal-regulated kinase 1/2 (MAPK/ ERK1/2) 
which can phosphorylate serine (Ser142) located on 
DNA binding domain of TRβ1 - a nuclear receptor 
of T3. This phosphorylation leads to dissociation of 
TRβ1 from corepressor proteins, the NCoR (nuclear 
receptor co-repressor) and SMRT (silencing 
mediator of retinoid and TH receptors) allowing for 
transactivation of T3-specific target genes. 
TETRAC and TRIAC (see ligands), which can 
inhibit nongenomic actions of TH, can also block 
the T4 potentiation of the antiviral and 
immunomodulatory actions of the interferon-γ, 
even though these analogues have no direct effect 
on the interferon-γ action. There is increasing 
evidence that nongenomic and genomic actions of 
TH may overlap with genomic and nongenomic 
effects of estrogens and testosterone in tumor cells. 
The thyroid hormone, estrogene and 
dihydrotestosterone have similar ERK1/2-
dependent proliferative actions on the estrogen 
receptor α (ERα)-positive human breast cancer 
cells. TH and steroids also have interacting 
nongenomic and genomic actions in heart and brain 
cells. The binding affinity of T4 to its plasma-
membrane receptor modulates intracellular protein 
trafficking of the ERα and TRβ1 receptors from the 
cytoplasm to nucleus. T4 -transduced activation of 
the ERK1/2 promotes its nuclear uptake and 
ERK1/2-dependent phosphorylation of the TRβ1, 
ERα and signal transducers and activators of 
transcription 3 and 1α (STAT1α, STAT3). In the 
nucleus of T4-treated cells, the TRβ1, ERα, 
STAT1α and STAT3 transcription factors were 
found to be co-immunoprecipitated with the 
activated ERK1/2. The complexing of TRβ1 and 
ERK1/2 was relatively rapid and detected with 1.4- 
and 7.8-fold increases in TRβ1 in 30 and 40 min of 
T4 treatment, respectively. This effect of T4 was 
observed as early as in 10 min and persisted for up 
to 90 min. The increase in nuclear TRβ1 was 
assumed to be originated from the pool of cytosolic 
fraction of the TRβ1. Interestingly, the nongenomic 
action of T4 has been shown to block the p53-
mediated proapoptotic activity of resveratrol, a 
polyphenolic compound found in grapes and wine 
(SIRT1 activator), by disrupting an ERK1/2-
nucleoprotein complex. Although, inhibition of T4 
binding at the cell surface receptor can restore the 
apoptotic action of the resveratrol (Lin et al., 2002). 
The action of T4 on cellular signal transduction is 
initiated at a cell-surface by activation of an 
integrin receptor - αvβ3 (identified in 2005). The 
TH plasma-membrane receptor was previously 
reported as a putative G protein-coupled receptor 
(GPCR) that preferentially binds T4 and 3,5,3',5'-
tetraiodothyroacetic acid (TETRAC), an antagonist 
of the nongenomic actions of TH (Lin et al., 1998; 
Lin et al.,1999). Extracellular binding of T4 to its 
transmembrane receptor was demonstrated to 
activate the signal transduction cascade which 
included G-proteins, PLC, PKC, Ras, Raf-1, 
MAPK kinase (MEK), the MAPK (ERK1/2) and 
downstream pathways (Davis et al., 2000). 
The current model of nongenomic actions of TH is 
based on transduction of the hormone signal 
through the membrane by the integrin αvβ3, which 
can preferentially bind T3 to S1 and T4 to S2 sites 
of the integrin (Davis et al., 2009). The signal 
transduction may result in pro-proliferative and pro-
angiogenic effects achieved in a ligand -dependent 
manner via the αvβ3/ERK1/2 cascade or by the 
hormone activated phosphatidylinositol 3-kinase 
(PI3K), respectively. The αvβ3 integrin is 
concentrated largely in plasma membranes of 
endothelial cells, vascular smooth muscle cells, 
various cancer cells, osteoclasts and platelets. 
Hormone-binding domain of the integrin receptors 
includes two recognition sites that are capable of 
binding T3 (S1) or T4 and T3 (S2). S2 site can bind 
both T4 and T3, though the affinity for T3 binding 
to the S2 site is lower than that for T4. Binding T4 
to integrin αvβ3 (without cell entry) may mediate 
nongenomic actions of TH by activation of 
extracellular-regulated kinases 1/2 (ERK1/2), which 
transduces the hormone signal into complex cellular 
and nuclear events including angiogenesis and 
tumor cell proliferation. This T4-induced pathway 
can stimulate shuttling of TRβ1 receptor from the 
cytoplasm to the nucleus and increase the TRβ-
mediated transactivation of specific genes. 
Moreover, phosphorylation of serine 142 located on 
DNA binding domain (DBD) of the 
cytoplasmic/nuclear TRβ1 is thought to facilitate 
transcription derepression by dissociation of 
corepressors (NCoR and SMRT) and recruiting 
coactivators and mediators (SRC-1, CBP, p300, 
pCAF, TRAP-DRIP). The nongenomic action via 
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integrin receptors may be specifically inhibited by 
TETRAC, a deaminated T4 analogue that can 
displace T4 and T3 from both sites (S1, S2) but 
does not mimic the agonist functions of the 
hormones through the integrin receptors. This T4-
analogue blocks thyroid hormone effects on 
angiogenesis and cancer cell proliferation and 
might have some benefits in cancer treatment. In 
the chick chorioallantoic membrane (CAM) model, 
the cells treated with TETRAC - an agonist for TRs 
(in genomic action), significantly enhance the 
expression of thrombospondin, an antiangiogenic 
gene. This effect has been shown to complement 
the anti-VEGF and anti-bFGF actions of TETRAC. 
In contrast, protein ligands present in extracellular 
matrix (ECM) and containing an Arg-Gly-Asp 
(RGD) motif fully inhibits T3 actions initiated at S1 
site (PI3K pathway) and does not affect T3 actions 
initiated at S2 site and ERK1/2-dependent cell 
proliferation. The S1 site can bind T3 exclusively 
and rapidly transduces the hormone signal via PI3K 
leading to cytoplasm-nucleus shuttling of TRα1 and 
expression of HIF1A gene encoding the hypoxia-
inducible factor-1α, alpha subunit (HIF-1α) (Davis 
et al., 2009). 
The similar activation of the HIF-1α transcription 
may be also initiated intracellularly by interaction 
of T3 with cytoplasmic fraction of TRβ1 (see 
diagram 5).The liganded TRβ1 mediates action of 
T3 on expression of specific genes, including pro-
angiogenic genes through binding to the regulatory 
subunit p85α of PI3K (see diagram 5) followed by 
activation of downstream cascade of protein kinase 
Akt/PKB, mammalian target of rapamycin (mTOR) 
and its substrate - p70S6K that is involved in 
cellular protein synthesis (Kenessey and Ojamaa, 
2006; Moeller et al., 2006). Activation of mTOR is 
rapid, with detectable phosphorylation within the 
minutes after T3 treatment. This pathway may lead 
to up-regulation of specific genes including: HIF1A 
and HIF-1α target genes; SLC2A1 (GLUT1) - 
solute carrier family 2 (facilitated glucose 
transporter), member 1; PFKP - 
phosphofructokinase, platelet; SLC16A4 (MCT4) - 
solute carrier familymonocarboxylate transporter 4; 
RCAN2 regulator of calcineurin 2 (ZAKI-4). 
Rapamycin - an inhibitor of mTOR, abrogates the 
thyroid hormone-dependent induction of the ZAKI-
4α, suggesting the role of sequential activation of 
the kinases in the PI3K pathway. Treatment of 
endothelial cells with T3 leads to activation of the 
Akt/PKB and endothelial nitric oxide synthase 
(eNOS) that is abolished by PI3-kinase inhibitors, 
but not by the inhibitors of transcription. The PI3K-
mediated effects are important to angiogenesis and 
other recently appreciated cell functions but not to 
tumor cell division. The T3 liganded TRβ1 in 
cytoplasm may also nongenomically initiate a 
process that result in transcription of the ATP1A1 
(ATPase, Na+/K+-ATPase) and insertion of the 
gene product into the plasma membrane (Davis et 
al., 2009). 
Regardless of TRβ1, also TRα1 can interact with 
the p85α subunit of PI3K in a T3 -dependent 
manner, leading to phosphorylation of Akt and 
activation of downstream signaling pathways. The 
other nongenomic actions of the TH have been also 
shown to modulate cellular ion fluxes, sodium 
current (I(Na)), inward rectifying potassium current 
(IKir), sodium pump (Na, K-ATPase) and ERK1/2-
regulated Na/H exchanger (NHE) encoded by 
SLC9C1 - solute carrier family 9 subfamily C 
(Na+-transporting carboxylic acid decarboxylase), 
member 1. Both, the genomic and nongenomic 
actions of TH have been shown to proceed the 
transcription and activity of the sarcoplasmic 
reticulum Ca(2+)-ATPase (calcium pump). T4 and 
rT3 but not T3 may act through a truncated form of 
TRα1 (TR∆α1) located in cytoplasm, wherein the 
liganded TR∆α1 may take part in conversion of 
soluble actin to fibrous (F) actin that is important to 
cell motility. Certain of these actions appear to 
interfere with genomic function of the TRβ 
receptors. The nongenomic effects of TRβ ligands 
occur rapidly and are unaffected by inhibitors of 
transcription or translation processes. 
THs exert important physiological actions by both 
genomic and nongenomic effects in mitochondria. 
T3 and T2 - a thyroid hormone metabolite, regulate 
mitochondrial genome transcription and 
nongenomically initiated mitochondrial processes 
such as cellular respiration and thermogenesis. T2 
metabolite binds and activates the mitochondrial 
cytochrome-c-oxidase Va, whereas T3 binds to two 
truncated TRα1 isoform (p28 and p43). Whereas 
the role of p28 remains unknown, p43 protein is a 
T3-dependent transcription factor of the 
mitochondrial genome, acting via dimeric 
complexes involving two other truncated forms of 
nuclear receptors: mtRXR and mtPPAR. All these 
mitochondrial actions as well as expression of other 
nuclear TH receptors (e.g. TRα1, TRα2) may have 
an impact on thyroid hormone availability and the 
TRβ function in the cell. 
Concluding this section, the nongenomic actions of 
TH that are mediated by TRβ is fast (10-40min), 
frequently reported to result in pro-proliferative, 
pro-angiogenic, anti-apoptotic effects and may be 
simplified into two main signaling cascades: 1) 
extracellular-T4/ αvβ3-integrin/ PLC/ PKCα/ 
ERK1/2/ TRβ1-Ser142 phosphorylation that among 
others can result in specific gene transactivation or 
transrepression (see diagram 5N4); 2) cytoplasmic-
T3/ TRβ1/ CSH2-p85α-p110(PI3K)/ Akt/ mTOR 
phosphorylation leading to transcription of PI3K-
specific genes such as HIF1A and GLUT1 (diagram 
5N1, 5N1b, 5N1c). Specific inhibitors of these 
pathways are shown on diagram 5. 
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Interaction 
TRβ has been shown to interact with: BRD8, 
CCND1, NCOA1, NCOA6, NCOR2, NR2F6, 
PPARGC1A and RXRA. 
Crosstalk signaling with proteins of nuclear 
hormone receptor superfamily. 
Apart from TRβ proteins, the other T3 regulated 
nuclear receptors may affect the thyroid hormone 
levels and the TRβ function in cells. T3 and T4 
exert a pleiotropic effect on cellular homeostasis 
and are mediated by protein products of both the 
THRB and THRA genes. The THRA encodes 
TRα1, TRα2, TRα3 and some truncated variants 
TR∆α1, TR∆α2, p28 and p43. The TRα1 can 
display both a nuclear and cytoplasmic location, 
and is the only thyroid hormone receptor that is 
imported into the mitochondrial matrix as p28 and 
p43 truncated variants. The thyroid hormone 
receptor beta gene may produce TRβ1, TRβ2, TRβ4 
(in humans) and two additional isoforms expressed 
in rats: TRβ3 and TR∆β3. The TRα1, TRβ1, TRβ2 
as well as TRβ3 can bind T3 and mediate T3-
dependent actions, thus, the proteins are bona fide 
receptors, whereas the TRα2, TRα3 or TR∆α1 
TR∆α2, TR∆β3 and TRβ4 do not bind the hormone 
and their function remains to be elucidated. The 
TRα2 and TRα3 have longer carboxy-terminal 
domains (AF2) that does not bind T3 and weakly 
binds DNA, thus, the variants act as dominant 
negative antagonists of T3 signalling. The truncated 
variant TR∆β3 lacks the DNA-binding domain but 
retains T3 binding activity and acts as a dominant-
negative antagonist. The human variant TRβ4 that 
is a C-terminal spliced variant of TRΒ1 lacks T3 -
binding ability and acts as an endogenous 
dominant-negative isoform. The TRβ4 weakly but 
significantly inhibits transcription mediated by 
functional T3 receptors. 
The function of the TRβ proteins may be influenced 
by the other members of the receptor superfamily 
that may lead to either synergistic or antagonistic 
effects. The nuclear receptor superfamily includes 
the estrogen receptor-like subfamily liganded by 
estrogene (ER) or 3-ketosteroids: glucocorticoid 
(GR), progesterone (PR), androgen (AR), 
mineralocortycoid (MR) and the thyroid hormone 
receptor-like subfamily that consists of the nuclear 
receptors for the thyroid hormone (TRα, TRβ), liver 
X receptor-like proteins (LXR, FXR), vitamin D 
receptor-like proteins (VDR, PXR, CAR), retinoic 
acid receptors (RARs) and peroxisome proliferator-
activated receptors (PPARs). This subfamily also 
include the heme receptors: Rev-ErbAα encoded by 
NR1D1 gene that regulates various cellular function 
including circadian cycle and the ratio of 
TRα1/TRα2 isoforms as well as Rev-erbβ (NR1D2) 
identified in the THRB locus (3p24.2, see diagram 
2). These heme binding receptors were identified 
previously as "orphan" (unknown ligand and/or 
DNA target) receptors. The members of the thyroid 
hormone receptor-like subfamily are classified as 
type II nuclear receptors, which are retained in the 
nucleus and can bind to DNA regardless of the 
ligand binding status and usually form heterodimers 
with Retinoid X Receptor-like subfamily 
transcription factors, which includes the retinoid X 
receptor (RXR), hepatocyte nuclear factor-4 
(HNF4), testicular receptor (TR2, TR4) and 
photoreceptor cell-specific nuclear receptor (PNR). 
The class II receptors include the members of the 
estrogen receptor-like subfamily as well. 
Interactions in the nuclear superfamily could be 
illustrated on the basis of crosstalk signaling 
between TRs and PPARs. This interaction appears 
to be important in TRs -mediated adipogenesis and 
carcinogenesis. Majority of the effects of PPARs 
and TRs were found to be opposing during the 
crosstalk, however the cooperative effects were 
reported as well (Lu and Cheng, 2009). PPARs 
liganded by prostaglandins, prostacyclins or a 
conjugated linoleic acids (CLAs) and T3 liganded 
TRs can reciprocally affect the target gene 
expression. In humans, the DBDs of TRs and 
PPARs are highly homologous and can bind to the 
same half-site sequence that is present in both, TRE 
and PPRE elements. The canonical DR1 PPRE 
consists of two direct repeats of AGGTCA with a 1 
bp spacer, whereas the DR4 TRE is built by the 
same direct repeats, separated with a 4 bp spacer. 
TRs can competitively bind to PPREs of PPAR 
target genes. Moreover, either TRs or PPARs 
compete with the other receptor for binding to RXR 
that may result in decreased availability of RXR 
and reduced transcriptional activity of the PPAR 
target genes. Consequently, the PPARγ agonist 
rosiglitazone is able to reverse the effects of 
dexamethasone and to increase serum T3 and T4 
levels. Interestingly, in rats with a high-fat diet and 
in a hyperthyroid state, administration of the 
PPARα agonist Wy14,643 restores glucose 
tolerance by enhancing glucose-stimulated insulin 
secretion and relieves the effect of hyperthyroidism. 
These data suggest that PPARα activity may restore 
the pancreatic islet function affected by abnormal 
T3/TR signaling. Furthermore, the genomic 
crosstalk of these two receptors may occur also via 
nongenomic actions of the receptors (Lu and Cheng 
2009). 
Ligands and metabolites 
L-thyroxine (T4), a major secretory product of 
thyroid gland, and 3, 5, 3'-triiodo-L-thyronine (T3), 
the most active form of thyroid hormone are 
naturally occurring ligands for TRβ receptors. T3 is 
a tyrosine-based derivative of T4 that is produced 
by the thyroid gland in response to thyroid-
stimulating hormone (TSH) from the anterior 
pituitary. The TSH is released by thyrotropin-
releasing hormone (TRH) from the paraventricular 
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nucleus (PVN) of the hypothalamus and T4 
synthesis is controlled by negative feedback loop: 
hypothalamic-pituitary thyroid (HPT) axis. Free 
thyroid hormones in the circulation act negatively 
on the pituitary and hypothalamus, thus reducing 
the release of TRH, TSH and finally T4 and T3 
concentration in plasma. In the nucleus, the thyroid 
hormones bind TRβ with high affinity and 
specificity with Kd values in the nM range. Most T4 
and T3 in the circulation are bound to proteins 
including Thyroxine-binding globulin (TBG), 
transthyretin and albumin. This proteins are 
responsible for carrying the thyroid hormones in the 
bloodstream. 
Under normal conditions only a small fraction of 
T3 is generated by the thyroid gland, the remainder 
of T3, which is available for binding sites in the 
plasma and body cells, is synthesized by mono-
deiodination of T4, that is inactive and needs to be 
converted to T3 what occurs in peripheral tissues. 
The reaction is catalyzed by type 1 (DIO1, 
EC1.97.1.10) or type 2 (DIO2, EC 1.97.1.11) 
iodothyronine deiodinases (selenoproteins), the first 
is abundant in kidney, liver and thyroid whereas the 
last one is mainly present in brown adipose tissue, 
pituitary and central nervous system. DIO1 is 
sensitive to inhibition by the anti-thyroid drug 
propylthiouracil (PTU). The enzyme activity of the 
kidney and liver is responsive to the nutritional 
status of an organism and is found to be more active 
during states of accelerated glucose metabolism. 
Most T3 molecules are produced by enzymatic 
outer ring deiodination (ORD) of T4. Alternative, 
inner ring deiodination (IRD) of T4 yields the 
metabolite rT3. ORD is regarded as an activating 
pathway and IRD as an inactivating pathway. DIO1 
shows the ORD and IRD activity, DIO2 only ORD 
activity and the third iodothyronine deiodinase - 
DIO3 (expressed above all in brain tissue) mediates 
only the degradation of thyroid hormone since it 
has only IRD activity. T3 and rT3 undergo further 
deiodination to the common metabolite 3,3'-
diiodothyronine (3,3'T2), which is generated by 
IRD of T3 and by ORD of rT3. Recent evidence for 
binding of T2 by a subunit of mitochondrial 
cytochrome c oxidase and its stimulation appears to 
be of a receptor/effector nature, showing as well 
that the T2 metabolite may have an important 
biological role that influences cellular respiration. 
Apart from T4, T3, rT3 and 3,3'T2, the other 
thyroid hormone derivatives have been shown to 
take part in iodothyronine-like endogenous 
signaling, which may includes T2 (3,5-diiodo-L-
thyronine), TAMs (thyronamines), and sulfate or 
glucuronic acid derivatives of thyroid hormones. 
The most commonly studied TRs agonists are: 
TRIAC (3,5,3'-triiodothyroacetic acid showing 
thyromimetic activity, TRβ selective), TETRAC 
(tetraiodothyroacetic acid, an inhibitor of T4-
transduced, αvβ3-integrin-mediated pathway), 
DITPA (3,5-diiodothyropropionic acid), DIMIT 
(3,5-dimethyl-3'-isopropylthyronine), GC-1 (3,5-
dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)-
phenoxy acetic acid (sobetirome), a TRβ-selective), 
KB-141 (3,5-dichloro-4-[(4-hydroxy-3-
isopropylphenoxy) phenyl] acetic acid), SKF 
94901(3,5-dibromo-3'-pyridazinone-L-thyronine). 
TETRAC expresses nucleus-mediated 
thyromimetic activity, though current studies 
demonstrated its role in suppression of T4-induced 
αvβ3-integrin/ERK1/2 pathway (Davis et al., 2009). 
Covalently bonded to a nanoparticle, TETRAC acts 
exclusively at the cell surface TH αvβ3 integrin 
receptor without the thyromimetic activity and TR-
mediated effects in nucleus. 
TRs agonist relative potencies: GC-
1~T3~TRIAC~T4>>rT3 have been determined for 
both coactivator recruitment and corepressor 
dissociation. 
The TRβ and liver selective thyromimetics 
(STRMs) such as GC-1 (sobetirome), KB2115 
(eproterome), KB141 and MB07811 have been 
developed to selectively lower serum total and LDL 
cholesterol without affecting HDL cholesterol 
levels and induce weight loss without deleterious 
effects on heart and combat other aspects of 
metabolic disease. GC-1 is the first TRβ agonist. 
KB141 is a selective TRβ agonist that can bind with 
an affinity 14-fold higher than that for TRα and is a 
useful candidate for attenuating the features of 
metabolic syndrome. This agonist lowers 
cholesterol, causes significant weight reduction in 
primates and has a 10-fold window in which 
therapeutic increases in metabolic rate are seen 
without cardiac hypertrophy or tachycardia 
therefore is a promising candidate for treating 
obesity, hyperlipidemia and diabetes. KB2115 has 
been described as a TRβ-selective agonist that is 
preferentially taken up by the liver and is also 
effective in patients on statin therapy. MB07811 is 
a liver-selective pro-drug that after hepatic 
activation through enzymatic cleavage is converted 
to the active form MB07344 - a strong TRβ ligand 
binding the other TRs with significantly lower 
affinity. Selective targeting with TRβ agonists may 
present an innovative strategy for searching for 
TRβ-specific effects. 
The most commonly studied antagonists are: 
DIBRT (3,5-dibromo-4-(3'5'-diisopropyl-4'-
hydroxyphenoxy)benzoic acid) and NH-3 (4-(4-
hydroxy-3-isopropyl-5-(4-nitrophenylethynyl) 
benzyl)-3,5-dimethylphenoxy) acetic acid (NH-3, a 
low affinity TR antagonist). The TRβ-selective (but 
not TRα-selective) agonists and antagonists are 
expected to alter gene expression in a TRβ biased 
manner that can differ from T3, which binds the 
two TRs with similar affinity. Amiodarone (Amio) 
and dronedarone (Dron) are drugs used to 
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discriminate between TRα1 or TRβ1 regulated 
genes in central and peripheral TH metabolism. A 
major metabolite of Amio, desethylamiodarone, 
acts as a TRα1 and TRβ1 antagonist, whereas the 
major metabolite of Dron -debutyldronedarone acts 
as a selective TRα1 antagonist that allows the TRβ1 
effects to become apparent. 
Homology 
Human THRB gene is reported to be conserved in 
Euteleostomi and has orthologs identified in: Pan 
troglodytes (Chr3, NCBI protein reference 
sequence: XP_001163850.1), Macaca mulatta 
(Chr2, XP_001090554.1), Canis lupus (Chr23, 
XP_862690.2), Bos taurus (Chr27, 
XP_002698801.1), Mus musculus (Chr14 7.08 cM, 
NP_001106888.1), Rattus norvegicus (Chr15 p16, 
NP_036804.2), Danio rerio (Chr19, NP_571415.1) 
and Gallus gallus (Chr2, erythroblastic leukemia 
viral (v-erb-a) oncogene homolog 2, avian, 
NP_001239150.1); according to the NCBI 
HomoloGene. Since the THRB shows multiple 
alignment, pairwise similarity scores and 
evolutionary distances, additional putative 
orthologs are likely in a variety of different species 
and can be viewed using alignment tools (BLAST, 
NCBI Resources). 
This gene is highly homologous to ERBB2 (v-erb-
b2 erythroblastic leukemia viral oncogene homolog 
2, neuro/glioblastoma derived oncogene homolog 
(avian)). A connection between TRβ1 and cancer 
became evident when the chicken TRα1 ortholog 
was characterized as the c-erbA proto-oncogene, 
the cellular counterpart of the retroviral v-erbA 
oncogene. However, a growing number of 
evidences suggest that TRβ could serve as a tumor 
suppressor. 
THRB is a member of a large superfamily of 
nuclear hormone receptor genes (see interactions) 
and displays extensive structural and functional 
similarity with the paralogous gene - THRA, which 
evolved from a common ancestor gene, duplicated 
500 Mya. The gene is duplicated at least in 
vertebrates, birds and amphibians. Divergent 
evolution of the genes increased the variety of 
cellular responses to TH in vertebrates. The 
paralogous THRB and THRA show 77% of mRNA 
coding sequence (CDS) identity and 84% of protein 
identity. The similarities were determined based on 
the NCBI BLAST protein seq.: TRβ1 
(NP_000452.2) ver. TRα1 (NP_955366.1); results: 
identities: 310/367(84%); positives: 342/367(93%); 
gaps: 0/367(0%); method: Compositional matrix 
adjust. NCBI BLAST mRNA CDS seq.: TRβ1 
(NM_000461.4) ver. TRα1 (NM_199334.3); 
results: identities: 854/1113(77%); score 814 
bits(902); gaps: 16/1113(1%). Comparative DNA 
analysis of the THRB and THRA revealed 10 
conserved fragments of at least 261bp in length (73-
90% of DNA identity between the genes), located 
in THRB introns: downstream of exon 1 (4x); 2a 
(2x), 2b, 3 (2x) and 4. These Alu-like elements 
were found in 5'-end of THRA sequence as well as 
in NR1D1 and NR1D2 genes. Moreover, two full-
length of ADAR-binding sequence motif flanking 
A-to-I RNA editing sites (Ramaswami et al., 2012) 
are present in introns before exon 2a and 2c of the 
THRB. This consensus sequence is also present in 
THRA and NR1D1 genes. 
The other reported paralogs for THRB gene are: 
VDR, NR4A3, NR4A1, NR1I2, RARG, NR1I3, 
RARA, NR1H2, NR4A2, NR1H4, RARB, NR1H3. 
Interestingly, the THRB has close structural and 
functional relatives in NR1D2 (in the same locus), 
which encodes Rev-erbβ as well as THRA 
encoding TRα1 and TRα2 isoforms and NR1D1 
gene expressing Rev-erAα. The THRB and NR1D2 
genes are also linked to the RARB encoding RARβ. 
Since it has been shown that the THRA/NR1D1 
locus is also linked to the RARA gene, these data 
suggest that the two receptor gene clusters 
RARA/THRA/NR1D1 and RARB/THRB/NR1D2 
were generated by a single large-scale duplication. 
Moreover, the THRA gene shares a partial overlap 
with the NR1D1 gene that influences the 
TRα1/TRα2 ratio. Similar regulation may occur in 
case of the TRβ transcripts and the products of the 
genes sharing the same DNA sequence with the 
THRB (see diagram 1 and 2). The genes located in 
the same locus may produce long naturally 
occurring antisense transcripts (cis-NATs) forming 
sense-antisense pairs with a single stranded DNA or 
transcripts of the THRB. These sense-antisense 
pairs may activate a pseudogene-mediated 
regulation (see Pseudogene). 
Reference conserved domains on TRβ1 protein 
(Homo sapiens, NP_001121649.1): 1) cd06961: 
NR_DBD_TR superfamily, DNA-binding domain 
of thyroid hormone receptors, Heterodimer 
interface of human Thyroid Hormone; 2) cd06935: 
NR_LBD_TR superfamily, The ligand binding 
domain of thyroid hormone receptor, coactivator 
recognition site (polypeptide binding site), dimer 
interface (polypeptide binding site). 
Reference conserved domains on TRβ2 (Homo 
sapiens): 1) cd06929: NR_LBD_F1 (aa : 281-454), 
Ligand-binding domain of nuclear receptor family 
1; 2) cd06916 : NR_DBD_like (aa : 122- 194) 
DNA-binding domain of nuclear receptors is 
composed of two C4-type zinc fingers. 
Animal models 
Animal models imply close associations between 
aberrant expression of TRβ or TRβ mutants and 
pathogenesis of some diseases, such as dominant or 
reccessice Generalized Resistance to Thyroid 
Hormone (GRTH) and Follicular Thyroid 
Carcinoma (FTC). Creation of a mouse model that 
harbors a knockin mutation of TRβ has facilitated 
THRB (Thyroid Hormone Receptor, Beta) Master A, Nauman A 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(6) 416 
the study of the molecular actions of TRβ mutants 
in vivo. Knock-out studies in mice suggest that the 
different TH receptors may mediate different 
functions, though several studies of TRs actions 
revealed near complete overlaps in their effects. 
Tissue-specific expression of TRβ isoforms is 
thought to be a major factor responsible for the 
observed differences in phenotypes, including those 
that are affected by TRβ mutations. In mice knock-
outs, the TRβ abnormalities may affect the 
following systems: endocrine/exocrine glands 
(increased thyrotroph cell number, enlarged thyroid 
gland, abnormal pituitary gland physiology); 
hearing/vestibular/ear (abnormal cochlea 
morphology, increased or absent threshold for 
auditory brainstem response, sensorineural hearing 
loss); homeostasis/metabolism (increased 
circulating thyroid-stimulating hormone level); 
nervous system (increased thyrotroph cell number, 
abnormal pituitary gland physiology, decreased 
cochlear outer hair cell number, abnormal retinal 
cone cell morphology); skeleton (spiral ligament 
degeneration), vision/eye (abnormal retinal cone 
cell morphology). 
THRB gene, like mice Thrb ortholog, encodes TH 
receptor isoforms TRβ1 TRβ2 and TRβ4. 
Moreover, function of these receptors may be 
influenced by two additional isoforms: TRβ3 and 
TR∆β3, expressed in rat models (Williams et al., 
2000). TRβ1, TRβ2, and TRβ3 are bona fide T3 
receptors that bind DNA, T3 and regulate 
expression of T3-responsive target genes. Studies 
of Trβ and Trβ2 knockout mice indicated that Trβ1 
is essential for development of auditory function, 
whereas Trβ2 is not required, but that Trβ2 alone is 
essential for development of mid-wavelength (MW) 
cones photoreceptors. In contrast, both Trβ1 and 
Trβ2 are required for regulation of hypothalamic-
pituitary-thyroid axis. The Trβ2 deletion in mice 
induces a complete and selective loss of MW-cone 
opsin without significant changes in total cone 
numbers. TRβ3 and TR∆β3 variants are transcribed 
using third promoter (P3) positioned upstream of 
human exon 5 and downstream of second promoter 
(P2) of TRβ2 (see diagram 3). TR∆β3 mRNA lacks 
rat exon B (315 nt) encoding a fragment of DNA-
binding domain, present in TRβ3, which contains 
both exon A (342 nt) and B of rat TRβ. Start codons 
of TRβ3 has been identified in frame in various 
animal Thrb sequences including mouse, dog, 
chicken but not in human, chimpanzee and 
macaque. Nevertheless, none of these ATG codons 
are positioned within a favorable Kozak translation 
initiation sequence context and the lack of murine 
TRβ3 or TR∆β3 expressed sequence tags (NCBI 
EST) suggests that in rats, expression from P3 
promoter is differentially regulated. TRβ3 is a 
functional T3 receptor and the most potent isoform, 
but dependent on the sequence context of TRE 
elements, whereas TR∆β3 retains T3-binding 
activity but lacks a functional DNA-binding domain 
and does not activate target gene transcription. 
Therefore, this isoform acts as a modulator (potent 
antagonist) of TRβ3 when coexpressed at low 
concentrations. At higher concentrations, TR∆β3 is 
a TRE-selective and cell-specific antagonist of 
TRα1, Trβ1, and TRβ3. Identified in humans TRβ4 
is a C-terminal variant that lacks the ligand binding 
domain (truncated variant of TRβ1), thus may 
function as a potent endogenous antagonist, 
however its expression and function in animals is 
unknown. 
Mice with targeted deletions in TR genes have 
provided understanding of the possible roles of the 
different TRβ isoforms. Knockout mice that are 
unable to produce theTRα1 receptor show 
subnormal body temperature and mild 
abnormalities in cardiac function, whereas mice 
which lack expression of both TRα isoforms were 
severely hypothyroid and die within the first few 
weeks of life. Mice with disruptions of the entire 
beta gene (TRβ1 and TRβ2) exhibit elevated TSH 
levels and deafness suggesting its role in auditory 
system, while mice with mutations disturbing only 
TRβ2 had elevated TSH, but normal hearing. These 
mutants allow determination of which functions of 
the different receptor isoforms are redundant and 
which are not. TRs play important roles in the 
pathogenesis of thyroid cancers and hepatocellular 
carcinoma (HCC). For instance, v-erbA, a mutant 
form of TR lacking ligand-binding ability, triggers 
HCC development in transgenic mice. Similarly, 
TRβPV (Kaneshige et al., 2000) mutation harmoring 
mice develope thyroid cancers (see exemplary 
mutants below). 
There are various mouse knock-outs for THRB: 
- TRβPV/PV; mutant thyroid hormone receptor 
kindred PV (Kaneshige et al., 2000); Synonyms: 
TRβPV; Allelic composition: homozygous 
TRβPV/PV and heterozygous TRβPV/+; Mutation 
details: PV has an unusual mutation in exon 10, a 
C-insertion at codon 448, which produces a 
frameshift of the carboxyl-terminal 14 amino acids 
of TRβ1. PV was derived from a patient (called PV) 
with severe RTH characterized by elevated thyroid 
hormone levels accompanied by normal TSH, short 
stature, goiter, and tachycardia. This naturally 
occurring mutation shows lost T3-binding, 
transactivation activities, and displays dominant 
negative activity. Moreover, PV strongly interferes 
with the transactivation activity of wild-type TRs in 
vitro and unlike the missense mutations or single 
amino acid deletion of TRβ found in other patients, 
this unique frame-shifted mutated sequence is 
immunogenic, for which high-affinity specific 
antibodies have been developed. TRβ PV mutant 
has been obtained by using homologous 
recombination and the CreyloxP System. Affected 
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systems: endocrine/exocrine glands, 
homeostasis/metabolism; Human disease model: 1) 
Thyroid Hormone Resistance (NCBI OMIM: 
274300, 188570); TRβ PV/+ and TRβ PV/PV mice 
faithfully reproduce human RTH - the TRβPV 
mutation was initially identified in a patient who 
has the syndrome of resistance to thyroid hormone 
(RTH). Mice expressing a single PV allele showed 
the typical abnormalities of thyroid function found 
in heterozygous humans (mutation of one copy of 
human THRB) with RTH that is characterized by a 
reduced sensitivity of tissues to the action of 
thyroid hormones. 2) Thyroid Carcinoma (OMIM: 
188470), pituitary tumors; TRβPV/PV mice but not 
TRβPV/+, spontaneously develop follicular thyroid 
carcinoma and pituitary tumors with tumor 
progression similar to human cancer. The 
homozygous PV mice exhibit severe dysfunction of 
the pituitary-thyroid axis, abnormal bone 
development and impaired weight gains. This 
phenotype is distinct from that seen in mice with a 
null mutation in the TRβ gene (TRβ-/-) 
demonstrating the interference of the mutant TRβ 
with the functions of the wild-type TRβ. TRβPV/PV 
mutants may serve also as molecular model for 
nongenomic actions of T3 condributing to thyroid 
carcinogenesis. The mutant mice allows the 
elucidation of oncogenic activity of the TRβ(PV) 
through cytoplasmic effects of T3 (see diagram 5 
N1). This nongenomic action is mediated by 
interaction of PV with p85α regulatory subunit of 
PI3K to activate the downstream AKT/mTOR, 
p70S6K and PI3K-integrin-linked kinase-matrix 
metalloproteinase-2 signaling pathways. The PV-
mediated PI3K activation leads to increased cell 
proliferation, motility, migration, and metastasis. In 
this regulation, a nuclear receptors corepressor 
NCoR competes with PV for binding to the p85α 
that result in reduction of the AKT-mTOR-p70S6K 
signaling. The NCoR protein levels are 
significantly lower in thyroid tumor cells than in 
wild type thyrocytes, allowing more effective 
binding of PV to p85α to activate the PI3K 
pathway, thereby contributing to tumor progression 
in the TRβPV/PV mutant mice (Guigon and Cheng, 
2009). 
- Thrbtm1Df; thyroid hormone receptor beta; targeted 
mutation 1, Douglas Forrest ; Synonyms: Thrb-, 
TRbeta- Allelic composition: homozygous, 
Thrbtm1Df/Thrbtm1Df involves: 129 S1/Sv * 
C57BL/6J; Mutation details: Insertion of a 
neomycin cassette into exon 3, disrupts both the 
beta1 and beta2 isoforms of this gene. This 
transcript revealed a deletion of exon 3 sequences, 
and fused beta1 exon 2 to exon 4 resulting in an 
aberrant open reading frame, which terminates early 
into exon 4. No functional protein is predicted from 
this transcript, as the essential DNA binding and T3 
binding domains not present; Affected systems: 
endocrine/exocrine glands, hearing/vestibular/ear, 
homeostasis/metabolism, nervous system but not 
behavior/neurological phenotype; Human disease 
model : Thyroid Hormone Resistance, Generalized, 
Autosomal Recessive - GRTH (OMIM: 274300). 
- Thrbtm3Few; thyroid hormone receptor beta; 
targeted mutation 3, Frederic E Wondisford; 
Synonyms: GS125 KI, TR-BetaGS; Allelic 
composition: homozygous, Thrbtm3Few/Thrbtm3Few, 
involves: 129* C57BL/6; Mutation details: 
Missense mutations were introduced at codons 125 
and 126 (exon 3), resulting in Glu to Gly and Gly to 
Ser substitutions.  
The substitutions were within the P-box of the first 
zinc finger and were shown, in vitro, to abolish 
DNA-binding while retaining the ability to interact 
with T3 and cofactors. Western blot analysis 
showed endogenous levels of protein in 
homozygous mutant mice; Affected systems: 
endocrine/exocrine glands, hearing/vestibular/ear, 
homeostasis/metabolism, nervous system; 
vision/eye; Human disease model: Thyroid 
Hormone Resistance, Generalized, Autosomal 
Recessive, GRTH (OMIM: 274300). 
- Thrbtm2Few; thyroid hormone receptor beta; 
targeted mutation 2, Frederic E Wondisford; 
Synonyms: TRbetadelta337T; Allelic composition: 
homozygous, Thrbtm2Few/Thrbtm2Few, involves: 
129X1/SvJ * C57BL/6; Mutation details: The 
deletion of 3 base pairs in exon 6, corresponding to 
a deletion that results in thyroid horomone 
resistance in humans, was introduced via site-
directed mutagenesis along with a neomycin 
selection cassette inserted into intron 5. The 
mutation in exon 6 affects the ligand-binding 
domain which is common to both isoforms 
produced from this locus; Affected systems: 
behavior/neurological, homeostasis/metabolism, 
nervous system; Human disease model: Thyroid 
Hormone Resistance, Generalized, Autosomal 
Dominant, GRTH (OMIM: 188570). 
- Thrbtm2Few/+; thyroid hormone receptor beta; 
targeted mutation 2, Frederic E Wondisford; 
Synonyms: TRbetadelta337T; Allelic composition: 
heterozygous, Thrbtm2Few/Thrb+, involves: 
129X1/SvJ * C57BL/6; Mutation details: (see 
Thrbtm2Few/Thrbtm2Few); Affected systems: 
behavior/neurological, homeostasis/metabolism, 
nervous system; Human disease model: Thyroid 
Hormone Resistance, Generalized, Autosomal 
Dominant, GRTH (OMIM: 188570). 
- Thrbtm1Df/tm1.1Syc; thyroid hormone receptor beta; 
targeted mutation 1, Douglas Forrest; Synonyms: 
Thrb-, TRbeta-; Allelic composition: heterozygous, 
Thrbtm1Df/Thrbtm1.1Syc, involves: 129S1/Sv * 
129S6/SvEvTac * C57BL/6 * C57BL/6J; Mutation 
details: see above; Affected systems: 
endocrine/exocrine glands, mortality/aging, 
tumorigenesis, respiratory system; Human disease 
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model: Thyroid Carcinoma, Follicular; FTC 
(OMIM: 188470). 
- Thrbtm1Few; thyroid hormone receptor beta; 
targeted mutation 1, Fredric E Wondisford; 
Synonyms: TRbeta2 null; Allelic composition: 
homozygous mutant mice Thrbtm1Few/Thrbtm1Few, 
involves: 129S4/SvJae; Mutation details: A PGK-
neo cassette replaced the transcription site, the 
entire Thrb2-specific exon, and the splice donor 
acceptor site. RT-PCR analysis of pituitary RNA 
confirmed the preservation of the Thrb1 isoform, as 
well as the absence of the Thrb2 isoform. Affected 
systems: endocrine/exocrine glands, 
homeostasis/metabolism but not 
hearing/vestibular/ear. 
- Thrbtm4Few; thyroid hormone receptor beta; 
targeted mutation 4, Frederic E Wondisford; 
Synonyms: TR-Beta-, TrbetaKO ; Allelic 
composition: homozygous, Thrbtm4Few/Thrbtm4Few 
involves: involves: 129 * C57BL/6; Mutation 
details: Exon 3 was replaced with a self-excising 
PGK-neo cassette. The deletion of exon 3 
putatively results in an aberrant open reading frame 
caused by the fusion of exons 2 and 4. Using a C-
terminal mAb, protein was undetected by Western 
blot analysis of homozygous mutant mice; Affected 
systems: all mentioned at the begining of this 
section. 
More information on the Mouse Genome 
Informatics website (Mouse Genome Database 
(MGD)). 
Mutations 
Note 
9555 human THRB variants (NCBI dbSNP) 
includind 8007 single nucleotide polymorphisms 
(SNPs) and 326 human variants (20 studies, NCBI 
dbVar) have been recorded in the NCBI databases. 
Moreover, 42 pathogenic variants of clinical 
significance including 31 germline SNP, 4 copy 
gain, 3 deletions and 3 insertions of the gene have 
been catalogued in the NCBI ClinVar database (see 
Table 1). These allelic variants have been identified 
to impair hormone binding, DNA binding or ligand-
dependent conformational changes. Some of them 
inhibits homodimer formation or stabilizes 
homodimer ligand-dependent conformational 
changes. The majority of the mutated TRβ receptors 
lost their trans-activation function and exhibited 
dominant-negative activity. 
Germinal 
There are 31 annotated germline THRB allelic 
variants in the NCBI dbSNP and ClinVar but only 
15 reported in dbVar of the NCBI. Most of them 
are SNPs and insertions or deletions are less 
frequently found. The most relevant SNPs are those 
located on hormone binding domain (see diagram 6 
and table 1). Some of them inhibits homodimer 
formation or stabilizes homodimer ligand-
dependent conformational changes.  
The majority of the mutated TRβ receptors lost 
their function of transactivation (e.g. DIO1, GH1) 
or transrepression (e.g. TSHB, TRH) in T3-
dependent manner.  
These variants usually act as dominant-negative 
mutants. Most of the germline, clinically associated 
mutations of the TRβ receptor have been identified 
in patients with autosomal recessive or dominant, 
generalized thyroid hormone resistance (RTH, 
OMIM: 188570, 274300 respectively) as well as 
selective pituitary thyroid hormone resistance 
(OMIM: 145650).  
Patients with RTH have got impairment of the 
mechanism negatively regulating the feedback of 
T4/T3 to the hypothalamic TRH and pituitary TSH 
genes by the mutated TRβ receptors. 
There are also studies showing the mutations in 
TRβ-DNA binding domain, in 5' and 3' mRNA 
untranslated regions (UTRs) and intronic variants 
with potential disease association.  
These allelic variants have been identified to impair 
transcription, alternative splicing, translation or 
TRβ protein function such as hormone binding, 
DNA binding, ligand-dependent conformational 
changes or corepressors/coactivators 
dissociation/association function (see references). 
Somatic 
There are no reference variants reported as somatic 
in the NCBI dbSNP and ClinVar databases, 
however 3 allele variants (ID: nsv429603, 
nsv429566, nsv429555) are present in the NCBI 
dbVar.  
Morover, several studies tested the hypothesis that 
the functions of TRβ could be impaired in various 
cancer tissues by somatic mutations (see 
references).  
For instance, Puzianowska-Kuznicka et al. (2002) 
tested this hypothesis in selected human thyroid 
papillary cancer. Based on cancer-derived cDNAs, 
they found that the mean expression levels of TRβ1 
mRNA and TRα1 mRNA were significantly lower, 
whereas the protein levels of both were higher in 
cancer tissues compared to healthy thyroid samples.  
Sequencing of TRβ1 and TRα1 cDNAs, cloned 
from 16 papillary cancers, revealed that mutations 
affected receptor amino acid sequences in 93.75% 
and 62.5% of cases, respectively.  
In contrast, no mutations were identified in healthy 
thyroid controls, and only 11.11% and 22.22% of 
thyroid adenomas had such TRβ1 or TRα1 
mutations, respectively.  
The authors summarized that the findings suggest a 
possible role for mutated thyroid hormone receptors 
in the tumorigenesis of human papillary thyroid 
carcinoma (NCBI OMIM: 188550). 
THRB (Thyroid Hormone Receptor, Beta) Master A, Nauman A 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(6) 419 
 
Table 1. Pathogenic variants of clinical significance, according to NCBI ClinVar.  
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Diagram 6. Clinically asociated amino acid variants of TRβ proteins. Graphic representation of three mutational "hot spots" 
in the TRβ ligand-binding domain, in which natural mutations have clustered. Crystallographic structure of the TRβ ligand binding 
domain (LBD, E) complexed with triiodothyronine (T3) and C-terminal domain T3-dependent transactivation (F) are shown on all 
four sides (A,B,C,D) to visualize listed (on the right) reference variants, which colour corresponds to each α-helix structures of 
LBD (rainbow colored, N-terminus in blue, C-terminus in red). Mutations in the LBD may be associated with resistance to thyroid 
hormone (RTH). The most frequent mutations in RTH are bolded. Substitutions associated with pituitary-specific RTH (PRTH, 
R338L, R338W, R429Q) and generalized RTH (GRTH, P453S, G345S) are given. Mutations of GRTH (P453S, G345S) impair 
both TRβ2 and TRβ1 function proportionally, whereas variants of PRTH disproportionately disrupt the function of TRβ2 (Wan et 
al., 2005). An increased inability of the mutants to properly release the nuclear corepressors is postulated to inhibit the T3-
mediated transactivation or transrepression of target genes. The TRβ mutants function in a dominant-negative fashion to 
interfere with the transcription activity of other wild-type thyroid hormone receptors (TRα) leading to resistance in peripheral 
tissues and dysregulation of the hypothalamic-pituitary thyroid axis (Dumitrescu and Refetoff, 2013). The conserved T3 binding 
domain was visualized using PyMOL 1.3 Molecular Graphics System, on the basis of crystallographic structure file (PDB: 1XZX) 
of the RCSB Protein Data Bank and The NCBI Conserved Domains Database (CDD, ref.c.d.: cd06961, NR_LBD_TR). For a 
more extensive listing of mutations, see references. 
 
The similar conclusion can be found in studies of 
Kamiya et al. (Kamiya et al., 2002), who have 
cloned and sequenced 22 cDNAs obtained from the 
human renal clear cell carcinoma (OMIM: 144700). 
Somatic mutations were found in 7 TRβ1 and 3 
TRα1 samples. These findings are consistent with 
the results obtained on hepatocellular carcinoma 
HCC (Lin et al., 1999). However, some data from 
direct genomic DNA sequencing provided an 
evidence that somatic THRB gene mutations may 
not be as common in differentiated thyroid cancers, 
in which hypermethylation of the gene was shown 
to be a major mechanism responsible for down-
regulation of the gene expression. Indeed, THRB 
has been proposed to serve as a novel epigenetic 
marker for early detection and prognosis of high 
grade serous ovarian cancer (Kashuba et al., 2013) 
and identified to be frequently methylated in 
prostate cancer, breast cancer, non-small cell lung 
cancer and acute lymphoblastic leukemia (Dmitriev 
et al., 2009; Dmitriev et al., 2012; Ling et al., 2010; 
Vasiljevic et al., 2011). Searching the cBio Cancer 
Genomics Portal (Cerami et al., 2012), currently 
providing access to data from more than 5000 
tumor samples from 20 cancer studies revealed that 
somatic mutations were the most frequently found 
in Skin Cutaneous Melanoma (up to 5.7% cases 
altered in the database).  
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The mutations were also reported in stomach 
adenocarcinoma (4.1%), kidney renal clear cell 
carcinoma (3.6%), colorectal cancer (2.8%), 
pancreatic adenocarcinoma (2.4%), colon and 
rectum adenocarcinoma (1.9%), head and neck 
squamous cell carcinoma (1.8%), lung 
adenocarcinoma (1.6%), ovarian serous 
cystadenocarcinoma (1.6%), uterine corpus 
endometrioid carcinoma (1.3%), sarcoma (1.2%), 
lung squamous cell carcinoma (1.1%), breast 
invasive carcinoma (0,9%) and acute myeloid 
leukemia (0,5%).  
Most of the cancer mutations were identified as 
substitutions, however deletions were the most 
frequently found in renal clear cell. There were also 
reported amplifications in pancreatic 
adenocarcinoma, kidney chromophobe renal cell 
carcinoma and sarcoma (Gao et al., 2013; see 
cBioPortal in external links). It is noticeable that 
the reported alteration frequency can vary in 
different studies depending on the target 
populations, number of tested samples, analytical 
methods and histopathological classification of the 
tumors. 
Somatic mutations/sequence variants have been 
shown to be created post-transcriptionally in 
various cancer-derived transcripts (Klimek-
Tomczak et al., 2006; Chen et al., 2013). Adenosine 
(A) to inosine (I) RNA editing of AZIN1 was 
demonstrated to be increased in the hepatocellular 
carcinoma and suggested as a potential driver in the  
pathogenesis of human cancers, particularly HCC. 
ADAR1-mediated A-to-I RNA editing was shown 
to change the RNA nucleotide sequence relative to 
that of the encoding DNA that was reported to 
result in cancer development and progression 
(Huang et al., 2013). ADAR belongs to the family 
of RNA specific adenosine deaminase, which acts 
on double-stranded RNA (dsRNA) substrats 
including those created by long naturally occurring 
antisence transcripts (cis- and trans-NATs) such as 
Rev-erbα/TRα2 or intra-THRB transcripts (see 
diagram 1). Then, inosine, which in RNA can pairs 
with cytosine (C) uracil (U) or adenine (A, 
generating wobble pairs), is recognized as 
guanosine (G) by ribosomes (translation) and 
reverse transcriptase during cDNA synthesis. In 
fact, the comparison of whole genome sequences 
and deeply sequenced transcriptomes of human 
lymphoblastoid cell line GM12878 and a Han 
Chinese individual (YH) allowed for identification 
of two mismatches corresponding to A/I(G) ediging 
sites within THRB sequence (DNA ref. sec. 
position: 24167619, 24321108) as well as several 
editing sites in NR1D2 gene (see diagram 1, 
genomic context, Ramaswami et al., 2012). The 
next-generation sequencing used in the study 
permitted comparing genomic DNA and RNA 
sequencing data from the same individuals. These 
preliminary findings, however obtained from non- 
cancerous samples, may indicate that the ADAR-
mediated RNA editing may change the sequence of 
THRB pre-mRNA post-transcriptionally 
(Ramaswami et al., 2012) and that this process may 
be impaired in numerous cancers (Huang et al., 
2013). 
Implicated in 
Thyroid related disorders and 
cancers 
Note 
THRB gene mutations (NCBI OMIN : 190160) are 
known to be a cause of several disorders including 
autosomal recessive or dominant, generalized 
thyroid hormone resistance (GRTH; NCBI OMIM: 
188570, 274300 respectively) as well as selective 
pituitary thyroid hormone resistance (PRTH; 
OMIM: 145650). Some forms of peripheral 
resistance to TH observed in familial euthyroid 
hyperthyroxinemia (OMIM: 145680) also appear to 
have a defect in the nuclear receptor for TH (Winter 
and Signorino, 2001). This gene has been also 
implicated in cancers such as follicular or papillary 
thyroid carcinoma (FTC, PTC; OMIM: 188470, 
188550 respectively). Disturbances of the THRB 
gene are frequent findings in numerous cancers 
including renal cell cancer (RCC; OMIM: 144700) 
as well.  
TRβ is a member of thyroid hormone receptors 
subfamily that mediates genomic and nongenomic 
actions of thyroid hormone (TH, T4/T3) that can 
influence cell growth, metabolism, apoptosis, and 
metastasis. TRβ mutations are involved in the 
reduced sensitivity to TH, short stature, attention-
deficit hyperactivity disorder, autoimmune thyroid 
disease, erythroleukemia, hepatocellular carcinoma, 
and thyroid carcinoma (Rosen et al., 2011). The 
reduced sensitivity to TH may include defects of 
transport, metabolism and action of TH. TRβ 
mutations have been identified to affect some of 
these processes (Dumitrescu and Refetoff, 2013). 
Clinically, effects of TH are observed as changes in 
metabolic rate, altered lipid metabolism, and 
characteristic effects on cardiovascular 
development. Aberrations in the levels of TH can 
cause multiple disorders, including cardiovascular 
disease, diabetes mellitus, chronic liver disease and 
is implicated in various cancers. Interestingly, TH 
can modulate response to interferon-γ and has 
potential therapeutic applications in hepatitis B and 
C (Chi et al., 2013). Knowledge of the molecular 
mechanisms involved in TH action allows the 
recognition of the phenotypes caused by defects of 
TH action including the syndromes of reduced 
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sensitivity to thyroid hormone (Dumitrescu and 
Refetoff, 2013). 
Carcinogenesis 
A close association of TRβ mutations with human 
cancers has become apparent, however the role of 
TRβ mutants in the carcinogenesis is still not clear 
(Weinert et al., 2012). Besides, a growing number 
of studies suggest that the THRB can function as a 
tumor suppressor (Guigon et al., 2013). This 
putative role of the gene is consistent with findings 
showing that four markers spanning the 3p24-p21.3 
region, THRB, AP20R, D3S1029, and D3S32, are 
regularly eliminated from three human chromosome 
3 (chr3)/mouse microcell hybrids (MCHs) during 
tumor growth in SCID mice. These studies 
indicated that tumor suppressor gene may be 
located in this area, as suggested by frequent loss of 
heterozygosity (LOH) within the region containing 
the THRB and observed in several types of solid 
tumors (Kholodnyuk et al., 1997). The loss of 
normal expression of the THRB gene due to 
truncation or deletion has been observed in many 
malignancies including kidney, lung, melanoma, 
breast, head and neck, uterine cervical, ovarian, and 
testicular tumors.  
Moreover, the epigenetic silencing of the THRB 
gene is common in human cancers. TRs play 
important roles in the pathogenesis of 
hepatocellular carcinoma (HCC).  
It has been shown that cloned TRα and TRβ are 
truncated or mutated at high frequencies in the 
human HCCs. TRβ1 isoform is essential for 
genomic actions of T3 in liver, wherein TH can 
influence hepatoma cell growth, metabolism, 
apoptosis, and metastasis.  
Therefore modulation of the TRβ-mediated actions 
of TH may have powerful therapeutic potential in 
clinical applications (Chi et al., 2013). Both TRα 
and TRβ have been shown to mediate action of T3 
that blocks the response to the oncogenic forms of 
the three ras isoforms (H-ras, K-ras, and N-ras). 
However, the TRβ isoform has stronger anti-
transforming properties than the TRα isoform and 
importantly can inhibit neuroblastoma 
tumorigenesis even in hypothyroid mice.  
These results show the existence of a transcriptional 
cross talk between the TRβ and the ras oncogene 
that may influence relevant processes such as cell 
proliferation, transformation, or tumorigenesis 
(García-Silva and Aranda, 2004).  
Furthermore, decreased THRB expression by 
promoter hyper-methylation has been reported in 
human breast cancer, lung cancer, and thyroid 
carcinoma, whereas reactivation of the silenced 
thyroid hormone receptor β gene expression delays 
thyroid tumor progression (Kim et al., 2013). 
Aberrant TRβ1 mRNA and protein levels have been 
reported to be a factor that may contribute to 
carcinogenesis in clear cell renal cell cancer 
(ccRCC). In this cancer, TRβ1 mRNA and protein 
levels were reduced by 70% and 91% in ccRCC 
and accompanied by absent DIO1 protein (a TRβ1 
target gene) and a 58% reduction in tissue T3 
concentration when compared to controls obtained 
from the opposite pole of malignant kidneys. These 
data provide an evidence of impaired T3 action in 
ccRCC that is maintained by reduced expression of 
TRβ1. The observed discordance in the magnitude 
of the change in TRβ1 mRNA level compared to 
protein (70/91 % reduction) together with the 
aberrant splicing of various TRβ1 5'UTRs leading 
to differences in the ratios of the variants may 
confirm that TRβ1 expression is subject to complex 
post-transcriptional regulation at least in ccRCC 
(Master et al., 2010). At this level, the gene is also 
regulated by microRNAs that are small endogenous 
noncoding RNAs binding to 3'UTR of the TRβ 
mRNA and affecting its level through RNA 
interpherence (RNAi) phenomenon. miR-21 and 
miR-146a have been found to inhibit the expression 
of the THRB by lowering the levels of both, TRβ 
mRNAs and proteins, suppressed down to 10-28% 
in papillary thyroid cancer (PTC) (Jazdzewski et al., 
2011). 
A knock-in mouse harboring a dominant negative 
Trβ mutation develops metastatic thyroid cancer 
that suggests the involvement of TRβ in 
carcinogenesis. The ThrbPV/PV mice (Kaneshige et 
al., 2000) harboring a knockin dominant negative 
PV mutation (see animal models), identified in a 
patient with resistance to thyroid hormone, 
develops the follicular thyroid carcinoma (FTC). 
The more aggressive thyroid tumor progression in 
the ThrbPV/PV mice results not only from the loss of 
tumor suppressor functions but also gain-of-
function in the oncogenic activities of the PV 
variant to drive thyroid carcinogenesis. Cell-based 
studies with simian virus-40 (SV40)-induced 
carcinogenesis demonstrated that TRβ can inhibit 
tumorigenesis by blocking the oncogenic actions of 
SV40-Tag via protein-protein interaction. The TRβ 
was shown to compete with Rb and 53 for binding 
to SV40-Tag oncoprotein that were accompanied 
by reduced cell proliferation and delayed cell entry 
from the cell cycle G1 to the S phase. In another 
research, estrogen (E2)-dependent growth of MCF-
7 cells that express the estrogen receptor, but not 
TRs, was inhibited by the expression of TRβ in the 
presence of T3. In a xenograft mouse model, large 
tumors rapidly developed after inoculation of MCF-
7 cells that lacks the TRs expression. Markedly 
smaller tumors (98% smaller) were found when 
MCF-7-TRβ cells were inoculated in athymic mice, 
indicating that TRβ can inhibit the E2-dependent 
cancer growth. This study provides additional in 
vivo evidence to support the hypothesis that TRβ 
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could act as a tumor suppressor in breast cancer 
development and progression. Moreover, cell-based 
studies in T47D, a breast cancer cell line, showed 
that T3 represses STAT5 signaling in TRβ-
expressing cells through decreasing STAT5-
mediated transcription activity and target gene 
expression whereas sustained STAT5 signaling was 
observed in TRβPV-expressing cells. The ThrbPV 
mutant increases the activity of STAT5 to increase 
cell proliferation and the expression of the STAT5 
target gene encoding β-casein in the mammary 
gland. Another transcription factor - STAT3 is 
frequently found to be activated in breast cancer 
cell lines and patients with advanced breast cancers. 
Importantly, the STAT3 as well as STAT1α are 
found to be activated as a result of nongenomic 
actions of T4 via αvβ3 integrins (Davis et al., 
2009), which are also responsible for activation of 
cytoplasmic fraction of TRβ1 via ERK1/2-mediated 
phosphorylation of its Ser142 (see nongenomic 
actions of TH). This pathway does not need to be 
mediated by genomic-actions of TRβ receptors and 
results in activation of the STAT3 and STAT1α that 
finally may lead to pro-proliferative, pro-
angiogenic and anti-apoptotic effects. The T4 action 
through αvβ3 integrins can be selectively blocked 
with a T4 analogue - TETRAC, without affecting 
the TRβ-mediated genomic actions of T3.  
In various reports, enhanced growth and 
proliferation of cancer cells are observed at low or 
high levels of the thyroid hormone, depending on 
the origin of cells or tissues examined. However, 
these confusing data could result from activation of 
different and cell-specific mechanisms involved in 
genomic and nongenomic actions of T4/T3. TH has 
been shown to be a ERK1/2-dependent growth 
factor for Human Myeloma Cells acting via αvβ3 
Integrin (Cohen et al., 2011). Several studies have 
demonstrated as well that T3 promotes growth and 
proliferation of cancer cells through TRβ1/Oct-1-
mediated cyclin D1 activation that was confirmed 
in papillary thyroid carcinoma cell lines (Perri et 
al., 2013). Decreased concentration of T3 has been 
also demonstrated to reduce proliferation of Caki-2 
cells in vitro (Poplawski and Nauman, 2008). There 
are studies indicating that elevated levels of TH 
may initiate direct effects on proliferation including 
those engaged in the regulation of cell cycle 
progression that may at least partially reflect the 
nongenomic actions of TH. Moreover, Thrb PV/PV 
mice (see animal models) treated with 
propylthiouracil (PTU), wchich blocks TH 
production, have been shown to reduce thyroid 
tumor growth by 42% when compared to control 
ThrbPV/PV mice (Lu et al., 2012). The tumor cell 
proliferation, invasion and metastasis was also 
decreased and accompanied by marked attenuation 
of the TRβPV/PI3K/AKT/β-catenin/cyclin-D2 
signaling pathway thus, showing a critical role of 
TH in promoting the thyroid carcinogenesis of 
ThrbPV/PV mice (Guigon and Cheng, 2009). 
Importantly, these findings suggest an anti-cancer 
potential of anti-thyroid drugs (Lu et al., 2012). The 
autors proposed a model in which the the TRβPV 
mutant directly interacts with PI3K to activate AKT 
signaling pathway. Suppression of TH in these 
cells, downregulates the membrane receptor 
integrin αvβ3 switching off a nongenomic action of 
T4. Furthermore, PTEN was found to be activated 
in these cells that can decrease the formation of 
PIP3, repress p-AKT and its downstream β-catenin 
and GSK3β signaling pathways, finally leading to 
inhibition of cell proliferation (Lu et al., 2012). In 
addition, TRβPV mutant is known to activate the 
TRβPV/PI3K/AKT signaling cascade via binding to 
p85α regulatory subunit of the PI3K competing 
with NCoR, which can also bind to p85α and 
repress this pathway (Guigon and Cheng, 2009).  
Besides, elevated levels of TRβ1 expression have 
been reported to reduce cell proliferation, malignant 
phenotype and to enhance apoptosis, indicating the 
suppressive role of the receptor, which is T3-
dependent at the genomic level. Furthermore, FTC-
236 cells, stably expressing TRβ, exhibited lower 
cell proliferation and migration through inhibition 
of β-catenin signaling pathways when compared to 
FTC-236 without TRβ. There are also studies 
indicating that the phenotype of tumors induced in 
hypothyroid hosts is more mesenchymal and their 
invasiveness and metastatic behaviour are 
enhanced. These findings are in line with reports 
documenting reduced tissue T3 in human gliomas 
(Nauman et al., 2004). Moreover, the reduced TRβ1 
expression and tissue hypothyroidism have been 
also reported in clear cell renal cell cancer 
(ccRCC). The level of T4 did not differ between 
normal and ccRCC tissues, whereas the 
concentration of T3 was reduced by 58% in ccRCC 
and was accompanied by 92% decrease of DIO1 
mRNA - a TRβ1 target gene (Master et al., 2010). 
These results are in agreement with genomic and 
nongenomic actions of TH that could be executed 
in ccRCC via T4-activated αvβ3-integrin/ERK1/2 
pathway (T4 levels were not altered) or 
TRβ1/p85/PI3K/Akt/mTOR pathway but not 
necessarily through TRβ-mediated genomic actions 
of T3 (low levels of TRβ1, DIO1, T3). These 
disturbances are likely to be involved in the process 
of carcinogenesis or in maintaining a proliferative 
advantage to malignant cells. Indeed, 
tetraidothyroacetic acid (TETRAC), a thyromimetic 
agonist of TRβ that can also block the T4 integrin 
(αVβ3) receptor at the cell surface, has been shown 
to inhibit growth of human renal cell carcinoma 
xenografts (Yalcin at al., 2009) and human 
medullary thyroid carcinoma (MTC) xenografts in 
the nude mouse (Yalcin at al., 2008). Interestingly, 
both the MEK/ERK- and PI3K/Akt-dependent 
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pathways mediate CD74-induced tumorigenesis of 
ccRCC and it is known that TRβ1 is involved in 
these signal cascades (see genomic and nongenomic 
actions of TH). The CD74 overexpression could not 
significantly induce the expression of TRβ target 
genes: HIF1A or HIF2A, what is in agreement with 
the low levels of T3 in ccRCC. T3 is required not 
only for genomic but also nongenomic actions 
mediated by TRβ1 in cytoplasm (see diagram 5) 
contributing to expression of PI3K-dependent 
genes, which includes the HIF1A (HIF-1α), 
SLC2A1 (GLUT1) and RCAN2 (ZAKI-4) genes. 
At the same time, TRβ1 nuclear import 
(cytoplasmic/nuclear localization) and its 
transcription factor activity depend on 
phosphorylation of TRβ1 Ser142 by ERK1/2.  
Simultaneously, TRβPV mutant has been 
demonstrated to activate cytoplasmic actions of T3 
via binding to CSH2 domain of p85α (see diagram 5 
N1c) (Furuya et al., 2009). This nongenomic action 
is mediated by direct protein-protein interaction of 
TRβPV with p85α regulatory subunit increasing the 
catalytic activity of p110 of phosphatidylinositol 3-
kinase (PI3K) to activate the downstream 
AKT/mTOR, p70S6K and PI3K-integrin-linked 
kinase-matrix metalloproteinase-2 signaling 
pathways. The TRβPV-mediated PI3K activation 
leads to increased cell proliferation, motility, 
migration, and metastasis (Furuya et al., 2009), but 
these effects are TH-dependent (Lu et al., 2012). In 
addition, a nuclear receptor corepressor (NCoR) as 
well as wild-type TRβ1 competes with TRβPV for 
binding to the C-terminal SH2 domain (CSH2) of 
p85α. Up-regulation of NCoR in thyroid tumor 
cells reduces AKT-mTOR-p70S6K signaling. In 
contrast, lowering cellular NCoR by siRNA 
knockdown in tumor cells results in over-activation 
of PI3K-AKT signaling. Importantly, NCoR protein 
levels are significantly lower in thyroid tumor cells 
than in wild type thyrocytes that allows for more 
effective binding of PV to p85α to activate the 
PI3K pathway, thereby contributing to tumor 
progression (Furuya et al., 2009). Furthermore, the 
suppressive role of TRβ has been demonstrated 
using MCF-7 cell line in xenograft models of 
estrogen-dependent tumorigenesis. The TRβ-
mediated inhibition of tumor growth has been 
elucidated via down-regulation of JAK-STAT-
cyclin D pathways (Park et al., 2013). Tumor 
suppressor function of TRβ has been demonstrated 
in a mouse model of metastatic follicular thyroid 
carcinoma as well (Zhu et al., 2010).  
According to the findings mentioned above, it could 
be hypothesized that TH may act as a growth, pro-
angiogenic, pro-proliferative and anti-apoptotic 
factor when initiated at the nongenomic level 
(Cohen et al. 2011; Davis, 2009), whereas in 
nucleus, TRβ1 could serve as a suppressor itself or 
mediating some genomic actions of T3 on specific 
genes involved in retardation of tumor growth and 
progression. (Martínez-Iglesias et al., 2009b; Kim 
at al., 2013). TRβ-dependent transrepression (see 
genomic actions of TH) is thought to be a 
mechanism that may have an important function in 
suppression of transforming effects of at least 
several oncogenes. The inhibitory action of T3 on 
ras-mediated transformation (Garcìa-Silva and 
Aranda, 2004) can be enhanced by over-expression 
of corepressors and reversed by silencing of the 
corepressors. This shows an important functional 
role of endogenous corepressors in suppression of 
transformation and tumorigenesis by TRβ1. All 
these findings raise the possibility that TRβ could 
act as a tumor suppressor in tumorigenesis. 
However, the presence of several TR isoforms, 
various TH metabolites, multiple transcription 
cofactors as well as simultaneous activation of the 
genomic and nongenomic actions of TH make its 
final effect more pleiotropic and less clear. 
Thyroid carcinoma, papillary (PTC) 
OMIM: 188550, MedGen UID: 66773. 
Synthesis and release of TH by follicular cells in 
the thyroid gland is regulated through the 
hypothalamic-pituitary thyroid (HPT) axis, a 
negative feedback loop controlled by both, the 
TRβ1 and TRβ2 isoformes. Nonmedullary thyroid 
cancer (NMTC) includes thyroid cancers of 
follicular cell origin and accounts for more than 
95% of all thyroid cancer cases (Vriens et al., 
2009). The remaining cancers originate from 
parafollicular cells - medullary thyroid cancer 
(MTC). NMTC is classified into: follicular, 
papillary, Hurthle cell, and anaplastic carcinoma. 
Dominant-negative TRβPV mutant (Kaneshige et al., 
2000) which lacks the C-terminus of the receptor 
(see animal models), causes severe disruption of the 
HPT axis, goiter, TSHomas, and metastatic 
follicular thyroid carcinoma (FTC). A double mice 
knockout of both TRα and TRβ results in a higher 
incidence of follicular thyroid carcinoma and 
increased aggressiveness in a skin cancer model. 
These animal models indicate the meaning of TRs 
in the pathogenesis of FTC. 
Disease 
Papillary thyroid cancer (PTC) is the most common 
subtype of FNMTC (familial NMTC), accounting 
for 72- 85% of cases. PTC occurs more frequently 
in women and in the 20-55 year age group. PTC 
appears as an irregular solid or cystic mass in a 
normal thyroid parenchyma and is characterized by 
distinctive nuclear alterations including grooves, 
pseudoinclusions, and chromatin clearing. PTCs 
that are smaller than 1 cm are referred to as 
papillary microcarcinomas. These tumors have been 
identified in up to 35% of individuals at autopsy, 
suggesting that they may be extremely common 
although rarely clinically relevant. PTC can also be 
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multifocal but is typically slow growing with a 
tendency to spread to lymph nodes and usually has 
an excellent prognosis. Activation of the mitogen-
activated protein kinase (MAPK) pathway as a 
result of mutations or somatic recombination is 
found in the majority of PTCs (Bonora et al., 2010). 
Prognosis 
Depending on source, the overall 5-year survival 
rate for PTC is 96-97%, whereas a 10-year survival 
rate is 93%.  
For younger patients, the prognosis is better than 
for patients older than 45 years (Ito et al., 2013; 
Biersack and Grünwald, 2005). 
Cytogenetics 
Germline mutations were found in approximately 
5% of NMTC, occurring as a primary feature 
FNMTC or as a minor component of a familial 
cancer syndrome (familial adenomatous polyposis, 
Carney complex) that are hereditary.  
Moreover, several cases of PTC including 
differentiated PTC have been reported to be 
associated with the RTH syndrome (Ramos-Prol et 
al., 2013). Furthermore, TRβ has been found to be a 
major target gene for microRNAs in PTC 
(Jazdzewski et al., 2011). Both, miR-21 and miR-
146a have been reported to inhibit the expression of 
the TRβ mRNA and protein, lowered down to 10-
28% in PTC (Jazdzewski et al., 2011). In addition, 
70% of PTCs have been shown to harbor point 
mutations of the BRAF and RAS genes or 
RET/PTC rearrangements, all of which can activate 
the mitogen-activated protein kinase pathways 
(Witt et al., 2013). For more information see 
Mutations. 
Thyroid carcinoma, follicular (FTC) 
Note 
OMIM: 188470, MedGen UID: 64630. 
TRs have been shown to serve as tumor suppressors 
in a mouse model of metastatic follicular thyroid 
carcinoma (Zhu et al., 2010). See Animal models. 
Disease 
Follicular thyroid cancer (FTC) accounts for 
approximately 15% of NMTC and occurs more 
commonly in women over 50 years of age. FTC is 
defined by invasive features that result in 
infiltration of blood vessels and full penetration of 
the tumor capsule as well as the absence of the 
nuclear alterations, which characterize papillary 
carcinoma. FTC is rarely multifocal and usually 
does not metastasize to the regional lymph nodes 
but tends to spread via the bloodstream to the lung 
and bones. The Oncocytic follicular carcinoma 
(Hurthle cell, oxyphilic) is an important histologic 
variant of FTC, composed of eosinophilic cells 
replete with mitochondria (Bonora et al., 2010). 
Prognosis 
The overall 5-year survival rate for FTC is 91%, 
whereas 10-year - 85% (Biersack and Grünwald, 
2005). 
Cytogenetics 
FTCs are known to harbor RAS mutation, PAX8/ 
PPARγ rearrangement and activation of the PTEN/ 
AKT pathway. These mutations are also mutually 
exclusive and identified in 70% of follicular 
carcinomas. Molecular classifiers measure the 
expression of a large number of genes on a 
microarray chip providing a substantial negative 
predictive value pending further validation. 
Aberrant THRB gene expression is thought to be 
implicated in FTCs (see Mutations and Animal 
models of FTC). 
Thyroid hormone resistance, 
generalized, autosomal dominant 
(GRTH) 
Note 
OMIM: 188570, MedGen UID: 424846. 
Resistance to TH (RTH), a syndrome of reduced 
end-organ responsiveness to TH, was identified in 
1967 (Refetoff et al., 1967) but linkage between a 
TRβ locus on chromosome 3 and the RTH 
phenotype was demonstrated in 1988 (Usala et al., 
1988). Recent discoveries of genetic defects that 
reduce the effectiveness of TH through altered cell 
membrane transport and metabolism broadened the 
definition of reduced TH sensitivity to include all 
defects that interfere with the biological activity of 
TH secreted in normal amounts (Dumitrescu and 
Refetoff, 2013). A number of humans with a 
syndrome of TH resistance have been identified to 
have mutations in the THRB gene (Dumitrescu and 
Refetoff, 2013). Clinically, such individuals show a 
type of hypothyroidism characterized by goiter, 
elevated serum concentrations of T3, T4 and near 
normal serum concentrations of TSH. More than 
half of affected children show attention-deficit 
disorder, which shows the role of thyroid hormones 
in brain development. THRB gene mutations 
produce two forms of generalized resistance to TH 
(GRTH) - autosomal recessive and dominant. The 
first one is less common and described in a family 
containing deletion of all coding sequences of the 
THRB gene that is inherited as an autosomal 
recessive trait (Takeda et al., 1992). The more 
common form of RTH is inherited in a dominant 
mode and is characterized by defects in only one 
allele of THRB, usually a missense mutation. The 
mutant THRB allele produces mutant TRβ protein 
that cannot mediate effects of T3 and acts by 
interfering with the function of the wild-type TRs 
(wt-TRs), finally contributing to a dominant 
negative effects (DNEs). The majority of the 
mutated TRβ receptors abolish ligand binding, lost 
their trans-activation function, and exhibited 
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dominant-negative activity. The TRβ mutants may 
disturb the wt-TRs binding to TREs or preserve the 
ability to dimerize with a partner (e.g. RXR). The 
DNE can be exerted also through reduced 
association with cofactors (CoAs) or increased 
affinity for corepressors (CoRs), which have been 
found to play a role in the autosomal dominant 
RTH. Indeed, mutants that fail to interact with 
coactivators or are defective in T3-induced release 
of corepressors have been identified in RTH 
patients. Importantly, the presence in a TRβ mutant 
of an additional mutation that abolishes either DNA 
binding, dimerization or the association with a CoR 
can result in the abrogation of the DNE 
(Dumitrescu and Refetoff, 2013). Moreover, RTH 
has been found to be modulated in vivo by the 
corepressor - NCoR1 (Fozzatti et al., 2011). Thus, 
full and potent dominant-negative activity of TRβ 
mutant requires functional DBD to retain the ability 
to bind DNA and to form homodimers and 
RXR/TR heterodimers.  
The findings reveal that dominant-negative activity 
in RTH is mediated by transcriptionally inactive 
complexes containing TR mutants bound to TREs.  
TRH is estimated to occur in approximately 1 per 
40000 newborns (Refetoff and Dumitrescu, 2007). 
The gene defect remains unknown in 15% of 
subjects with RTH.  
Familial occurrence of RTH has been documented 
in about 75% of cases, whereas incidence of 
sporadic cases has been reported in 21.0% of cases 
that is in agreement with estimate of the frequency 
of de novo mutations of 20.8%. RTH has been 
found with equal frequency in both male and 
female gender. The prevalence may vary among 
different ethnic groups however appears to have 
wide geographic distribution among Caucasians, 
Africans, Asians and Amerindians (Dumitrescu and 
Refetoff, 2013). 
Disease 
The majority of patients with RTH are identified by 
their persistent elevation of circulating free TH 
levels association with non-suppressed serum TSH 
and higher doses of exogenous TH are required to 
obtain appropriate secretion of pituitary TSH as 
well as the metabolic responses in peripheral 
tissues. The apparent resistance to TH may vary in 
severity and the magnitude of the hormonal 
resistance is mainly dependent on the nature of TRβ 
mutations. RTH shows a variable clinical 
presentation, however the common features of the 
RTH syndrome may include: elevated levels of free 
T4 and to a lesser degree T3, normal or slightly 
increased level of TSH responding to TRH, goiter 
and the absence of the metabolic consequences of 
TH excess. The frequency of the most frequently 
observed manifestations are as follows: thyroid 
gland: goiter 66-95%, tachycardia 33-75%, 
emotional disturbances 60%, hyperkinetic 
behaviour 33-68%, attention deficit hyperactivity 
disorder 40-60, learning disability 30%, mental 
retardation (IQ 2 SD 29-47, recurrent ear and throat 
infections 55% (Dumitrescu and Refetoff, 2013).  
Diagnosis is based on the clinical findings and 
standard laboratory tests including searching for 
germline mutations by sequencing of THRB exons. 
Nevertheless, a new role of 
mutations/polymorphisms within intronic 
sequences is recognised to affect alternative 
splicing and other events of post-transcriptional 
processing of TRβ RNA (Alberobello et al., 2011). 
Thus, the further association studies involving 
whole THRB sequencing (376 609 bp) would be 
needed to be carried out in patients with TRH 
symptoms who have no mutations in the THRB 
exons. Recently, the alternative splicing have been 
shown to produce human TRβ4 isoform, a 
carboxyl-terminal splicing variant of TRβ1 that 
contains a stop codon due to the presence of an 
intronic 137-bp insertion located between exon 7 
and 8. TRβ4 lacks the ligand binding domain and 
thus, may modulate T3 action as an endogenous 
dominant-negative protein. This variant is 
expressed in various human tissues regardless of 
mutation status in the coding sequence and may 
interfere with the function of wild-type TR 
isoforms (Tagami et al., 2011). 
Prognosis 
RTH affected individuals have elevated serum TH 
levels and normal or elevated TSH but are usually 
clinically euthyroid and require no treatment. 
However, the clinical presentation of RTH is 
variable and requires differential diagnosis 
excluding all other possible causes of 
hyperthyroxinemia. Most patients have normal 
growth and development, and lead a normal life at 
the expense of high TH levels and a small goiter. In 
some cases, abnormalities may be found in: 
connective tissue, head and neck, 
metabolism/homeostasis, abdomen, cardiovascular 
system, ear, eye, endocrine system, integument, 
musculature, nervous system, respiratory system, 
skeletal system and increased upper to lower 
segment ratio. Goiter has recurred in every patient 
who underwent thyroid surgery. As a consequence, 
some patients have been submitted to several 
thyroidectomies or treatments with radioiodide 
(Dumitrescu and Refetoff, 2013). 
Cytogenetics 
Mutations in THRB gene have been identified in 
approximately 85% cases of the RTH, however 
other genes such as MCT8 and SECISBP2 are 
believed to be associated with the disease as well 
(Bottcher et al., 2007). TRβ dominant negative 
mutants have been shown not only to fail its 
function in a transcriptional response to T3 but also 
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to interfere with wild-type TRα and TRβ actions. 
Haplotyping of intragenic polymorphic markers 
showed that, in most instances, identical mutations 
have developed independently in different families 
(Dumitrescu and Refetoff, 2013). Among 457 
families 170 different mutations have been 
identified and 78 of the mutations were shared by 
more than one family.  
Majority of the families (430) were found to have 
single nucleotide substitutions (SNP) resulting in a 
single amino acid substitution (419), stop codons 
producing truncated proteins (11). In 20 families, 
deletions, insertions and a duplication were 
identified.  
Most mutations were found in exon 9 and 10, 
however they were present in exon 6, 7, 8 as well. 
Unrelated families (33) shared the R338W 
mutation. Variants: R243Q, A317T, R338W, 
R423H and P453T were found in more than 15 
families.  
All TRβ gene mutations were located in the 
functionally relevant domain of T3-binding and its 
adjacent hinge region (see diagram 6). Three 
mutational clusters containing CpG hot spots have 
been identified (Dumitrescu and Refetoff, 2013). 
For more disease information, see references. 
Thyroid hormone resistance, 
generalized, autosomal recessive 
(GRTH) 
Note 
OMIM: 274300, MedGen UID: 333543. 
Recessively inherited resistance to thyroid hormone 
(RTH) is a rare autosomal disorder usually caused 
by mutations in the THRB gene. The loss of both 
THRB alleles may result in severe abnormalities 
reflecting unresponsiveness to TH. 
Disease 
A family with deletion of all coding sequences of 
the THRB gene has been reported to be inherited as 
an autosomal recessive trait (Takeda et al., 1992). 
The complete lack of TRβ in this family produces 
severe deafness, contributing to mutism and 
monochromatic vision (see Animal Models). 
Heterozygous individuals that express a single TRβ 
gene have no clinical or laboratory abnormalities. It 
has been demonstrated that this is not due to 
compensatory overexpression of a single normal 
allele of the THRB nor that of the THRA gene. 
However, normally expressed TRα1 is capable of 
partially substituting for the TRβ function 
(Dumitrescu and Refetoff, 2013). 
Cytogenetics 
The following homozygous mutations in the THRB 
have been identified: THRBdel (deletion of both 
alleles of THRB), T337del, I280S, G347, R316C 
(Ferrara et al., 2012). A novel rare homozygous 
mutation in the gene in position 1216 (G to A 
transition, codon 311) resulting in novel Glu-311-
Lys (p.E311K) substitution has been reported as 
well. The homozygous patient was characterized by 
severe symptoms of RTH. Both parents were 
heterozygous, suggesting autosomal recessive mode 
of the inheritance (Slezak et al., 2012). 
Thyroid hormone resistance, 
selective pituitary (PRTH) 
Note 
OMIM: 145650, MedGen UID: 333543. 
In contrast to GRTH, PRTH is characterized by 
resistance in the pituitary gland but not in 
peripheral tissues. Note that the anterior pituitary 
(secreting TSH) and in particular hypothalamus 
(releasing TRH) are brain structures wherein TRβ2 
is predominantly expressed. The presence of the 
TRβ2 isoform in cochlea, retina is extremely 
important during development (see Expression and 
specific functions). Due to the tissue-specific 
expression and function of the TR isoforms all 
tissues other than the pituitary have been grouped 
together under the term peripheral tissues. 
Disease 
This form of resistance to thyroid hormone is 
pituitary-selective and is characterized by 
hyperthyroidism and TRH-stimulated, inappropriate 
secretion of TSH (Gershengorn et al., 1975). 
Subjects with PRTH may have equally high levels 
of serum TH and non-suppressed TSH. These 
individuals may appear to be hypermetabolic, 
restless and may have sinus tachycardia or other 
thyrotoxic effects. In GRTH, the TH response of 
both the pituitary and peripheral tissues is 
disrupted, whereas in PRTH (designated also 
central), the ability of the pituitary to sense (and 
down-regulate) elevated TH is selectively impaired. 
Simultaneously, the peripheral tissues remains 
relatively TH-responsive that results in peripheral 
thyrotoxicity (Wan et al., 2005). It has been 
proposed that PRTH syndrome is associated with 
T3 receptor mutants that selectively impair β2 
isoform function in pituitary and hypothalamic cells 
(Wan et al., 2005). The wild-type TRβ2 isoform has 
been reported to display an enhanced T3 response 
relative to the TRβ1, expressed broadly in almost 
all tissues. In the normal subjects, and in GRTH, 
TRβ2 in the pituitary can sense rising T3 levels in 
advance of TRβ1 in the peripherial tissues, 
preventing the thyrotoxicity. In contrast, the THRB 
mutations associated with pituitary RTH (see 
diagram 6) disproportionately disrupt the pituitary's 
ability to sense and suppress elevated T3 levels in 
advance of the peripheral tissues, producing 
symptoms of the thyrotoxicity (Wan et al., 2005). 
Prognosis 
Prognosis depends on clinical manifestations and 
laboratory testing (see GRTH). There are some 
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difficulties in differentiating thyrotropin secreting 
pituitary microadenoma from pituitary-selective 
thyroid hormone resistance accompanied by 
pituitary incidentaloma (Akiyoshi et al., 1996). 
Importantly, THRB mutations have been found to 
be similar in both diseases (Dumitrescu and 
Refetoff, 2013). 
Cytogenetics 
Both forms, PRTH and GRTH are linked to 
mutations in THRB expressing TRβ1 TRβ2 and 
TRβ4 isoforms in tissue-specific pattern (see 
Diagram 2 and 3). Despite striking differences 
among the clinical presentations between these 
forms of RTH, there is a lack of direct genotype-
phenotype correlation and almost identical THRB 
gene mutations have been observed in PRTH or 
GRTH patients. Nevertheless, there are several 
association studies showing such correlations. 
Germline mutations associated with GRTH (P453S, 
G345S) have been reported to impair both TRβ2 
and TRβ1 function proportionally, whereas 
mutations associated with PRTH (R338L, R338W, 
R429Q) have been demonstrated to 
disproportionately disrupt TRβ2 function (Wan et 
al., 2005). Moreover, TRβ mutants R383H and 
R429Q have been shown to have greater 
impairment of transactivation on negatively than 
positively regulated promoters. These two mutants 
are candidates for predominantly PRTH, even 
though they have been clinically described as 
generating both, GRTH and PRTH. It has been 
proposed that the substitution of these charged 
amino-acids could disrupt the unique property of 
TRβ2 to bind coactivators through multiple contact 
surfaces. This may result in a decrease in T3-
mediated feedback suppression. Consequently, the 
mutation affects predominantly TRβ2 mediated 
action of TH (Dumitrescu and Refetoff, 2013). 
Another proposed mechanism for PRTH is a 
"double-hit" combining a SNP and the mutant 
R338W (Alberobello et al., 2011). Recent studies 
have demonstrated that an intron enhancer region 
may play a critical role in the pituitary expression 
of the TRβ2 isoform. It has been hypothesized that 
intronic polymorphisms in the intronic region could 
modulate the pituitary expression of the mutated 
gene contributing to the clinical presentation of 
RTH. The combined coding mutation such as 
missense R338W and two common SNPs 
(rs2596623T, rs2596622C) located in the intron 
enhancer region of the THRB gene can generate a 
tissue-specific dominant-negative conditions for 
development of the pituitary-selective RTH. 
Moreover, the results suggest that rs2596623T may 
lead to pituitary over-expression of the mutant 
allele (Alberobello et al., 2011). 
A novel TRβ variant - G339S has been found in 
several members of a family with elevated TSH, 
normal or low serum T4 and autoimmune thyroid 
disease (AITD) that was confounded with initially 
diagnosed RTH. This variant would not have an 
effect on the hypothalamic-pituitary-thyroid axis as 
determined by thyroid hormone binding in vitro and 
thyroid function tests in vivo (Larsen et al., 2013). 
Somatic mutations in the THRB have been 
identified in some TSH-secreting pituitary tumors 
(e.g. TSHomas). These mutations can be identical 
to those occurring in the germline. However, 
because their expression is limited to thyrotrophs, 
the phenotypes that of TSH induced thyrotoxicosis. 
It is postulated that defective TR interfering with 
the negative regulation of TSH by TH is 
responsible for the development of the pituitary 
tumor (Refetoff and Dumitrescu, 2007). 
Interestingly, TRβ4, a dominant negative variant of 
TRβ1, has been proposed to affect the function of 
wild type TRs in the TSHomas (Tagami et al., 
2011). 
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